dalteparin has been researched along with Thromboembolism in 498 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy." | 9.22 | Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism." | 9.13 | Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 9.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 9.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 9.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 9.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "Survival data were examined in a posthoc analysis in patients with solid tumors and venous thromboembolism who were randomly assigned to dalteparin or a coumarin derivative for 6 months in a multicenter, open-label, randomized, controlled trial." | 9.11 | Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. ( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005) |
| "125 patients treated as inpatients for atrial fibrillation or -flutter received the LMWH Fragmin (dalteparin 2 x 100 anti-Xa units/kg, maximum dosage 2 x 10,000 anti-Xa units subcutaneously)." | 9.10 | Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion. ( Bechtold, H; Fung, S; Gunzenhauser, D; Janssen, D; Sawitzki, H, 2003) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "To determine if a prophylactic dose of dalteparin, 5000 IU daily, and if the adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily are appropriate in pregnancy." | 9.09 | Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. ( Rey, E; Rivard, GE, 2000) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 9.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 9.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| " In a dose-ranging European study, preoperatively initiated subcutaneous melagatran 3 mg twice daily followed by oral ximelagatran 24 mg twice daily was significantly more effective than subcutaneous dalteparin sodium 5000IU once daily in preventing the occurrence of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement." | 8.82 | Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. ( Evans, HC; Faulds, D; Perry, CM, 2004) |
| "The fondaparinux trials in venous thromboembolism (VTE) prevention after orthopaedic surgery have been subject to methodological criticisms recently summarised in this journal." | 8.82 | The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. ( Turpie, AG, 2004) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 7.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "Today, there is a small number of studies on the effects of Enoxaparin and Fondaparinux used commonly in the prevention of venous thromboembolism on healing of fracture cases." | 7.79 | Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats. ( Alabalik, U; Azboy, I; Bulut, M; Demirtas, A; Necmioglu, NS; Ucar, BY, 2013) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients." | 7.73 | Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. ( Cohen, AT; Goldhaber, SZ; Kucher, N; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2005) |
| " The low-molecular-weight heparin dalteparin sodium is clinically effective in reducing the incidence of venous thromboembolism (VTE) in these patients." | 7.73 | Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. ( Heerey, A; Suri, S, 2005) |
| "The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined." | 7.72 | The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. ( Borris, L; Bossuyt, P; de Pouvourville, G; Gordois, A; Jönsson, B; Levy, E; Posnett, J, 2003) |
| "Many orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty." | 7.72 | Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. ( Brotman, DJ; Hurbanek, JG; Jaffer, AK; Morra, N, 2004) |
| "Our study suggests that dalteparin may be used for the treatment of acute venous thromboembolism in pregnancy." | 7.72 | Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. ( Jacobsen, AF; Qvigstad, E; Sandset, PM, 2003) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 7.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "A 15-month prospective cohort study of emergency department (ED) patients with suspected venous thromboembolism was conducted to assess the role of low molecular weight heparin (dalteparin) in an emergency setting in suspected venous thromboembolism prior to diagnostic confirmation." | 7.70 | Dalteparin in emergency patients to prevent admission prior to investigation for venous thromboembolism. ( Bauld, DL; Kovacs, MJ, 1999) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 6.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 6.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| " We did a multicentre, randomised, double-blind study to examine the dose-response relation of subcutaneous melagatran, a direct thrombin inhibitor, followed by oral ximelagatran as thromboprophylaxis after total hip or knee replacement." | 6.70 | Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. ( Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L, 2002) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 6.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| " The study did not evaluate a dose-response for efficacy, and no differences between the three dose levels of melagatran and ximelagatran were shown." | 6.70 | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002) |
| "Dalteparin or dextran was used during delivery." | 6.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| "The present trial was designed to comparatively investigate the pharmacokinetic profile and evaluate the apparent bioavailability pattern of three already marketed low molecular mass heparins (LMMHs): dalteparin (Fragmin), nadroparin (Fraxiparin), and enoxaparin (Lovenox) given by subcutaneous route." | 6.68 | Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ( Bouthier, J; Caplain, H; Collignon, F; Frydman, A; Le Roux, Y; Ozoux, ML; Thébault, JJ, 1995) |
| "One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb." | 6.68 | A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. ( Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Luomanmäki, K; Sörskog, L; Vilkko, P, 1996) |
| "Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation." | 6.41 | Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. ( Doggrell, SA, 2002) |
| "In this randomized, open-label, prospective superiority trial involving hospitalized patients with confirmed mild or moderate COVID-19 disease without known thromboembolism, we assigned 230 patients to receive either once-daily oral rivaroxaban (10mg or 15mg) or once-daily subcutaneous enoxaparin (40mg or 60mg) for a median duration of 8 days." | 5.51 | Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. ( Chandralekha, S; Kaimaparambil, V; Kumar, D; Lalchandani, J, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 5.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "To determine the efficacy and safety of dalteparin postoperative bridging treatment versus placebo for patients with atrial fibrillation or mechanical heart valves when warfarin is temporarily interrupted for a planned procedure." | 5.41 | Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. ( Anderson, DR; Bates, SM; Blostein, M; Kahn, SR; Kearon, C; Kovacs, MJ; Lazo-Langner, A; Ramsay, T; Rodger, MA; Sabri, E; Schulman, S; Solymoss, S; Wells, PS; Yeo, E, 2021) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 5.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy." | 5.22 | Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016) |
| "To assess the efficacy and safety of a dose range of PD 0348292 relative to enoxaparin for the prevention of venous thromboembolism (VTE)." | 5.17 | An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery. ( Boyd, RA; Cohen, AT; Dicarlo, L; Mandema, JW; Pak, R, 2013) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism." | 5.13 | Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 5.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "To estimate, from the perspective of Statutory Health Insurance (SHI, third-party payer) in Germany, the economic consequences of using the subcutaneous low-molecular-weight heparin (LMWH) enoxaparin instead of intravenous unfractionated heparin followed by oral phenprocoumon (UFH/PPC) for anticoagulation in patients undergoing transesophageal echocardiography (TEE)-guided early electrical cardioversion (ECV) of persisting nonvalvular atrial fibrillation (AF) without intracardiac clot." | 5.12 | Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. ( Brecht, JG; Huppertz, E; Lehmacher, W; Nixdorff, U; Schädlich, PK; Schmidt-Lucke, C; Stellbrink, C, 2007) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 5.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 5.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| "Enoxaparin is noninferior to UFH+phenprocoumon for prevention of ischemic and embolic events, bleeding complications, and death in TEE-guided cardioversion of atrial fibrillation." | 5.11 | Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) ( Daniel, WG; Geller, C; Hanrath, P; Hofmann, T; Lehmacher, W; Mügge, A; Nixdorff, U; Schmidt-Lucke, C; Schmidt-Lucke, JA; Sehnert, W; Stellbrink, C, 2004) |
| "Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery." | 5.11 | A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. ( Ahnfelt, L; Bravo, ML; Büller, HR; Dahl, OE; Eriksson, BI; Hettiarachchi, R; Kälebo, P; Piovella, F; Reilly, P; Rosencher, N; Stangier, J, 2005) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 5.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "Survival data were examined in a posthoc analysis in patients with solid tumors and venous thromboembolism who were randomly assigned to dalteparin or a coumarin derivative for 6 months in a multicenter, open-label, randomized, controlled trial." | 5.11 | Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. ( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005) |
| "In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding." | 5.10 | Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. ( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003) |
| "125 patients treated as inpatients for atrial fibrillation or -flutter received the LMWH Fragmin (dalteparin 2 x 100 anti-Xa units/kg, maximum dosage 2 x 10,000 anti-Xa units subcutaneously)." | 5.10 | Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion. ( Bechtold, H; Fung, S; Gunzenhauser, D; Janssen, D; Sawitzki, H, 2003) |
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| "We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty." | 5.09 | Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. ( Bigler, GT; Collis, DK; Colwell, CW; Hardwick, ME; Lutz, S; McCutchen, JW; Paulson, R, 1999) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "To determine if a prophylactic dose of dalteparin, 5000 IU daily, and if the adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily are appropriate in pregnancy." | 5.09 | Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. ( Rey, E; Rivard, GE, 2000) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 5.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 5.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| " In a dose-ranging European study, preoperatively initiated subcutaneous melagatran 3 mg twice daily followed by oral ximelagatran 24 mg twice daily was significantly more effective than subcutaneous dalteparin sodium 5000IU once daily in preventing the occurrence of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement." | 4.82 | Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. ( Evans, HC; Faulds, D; Perry, CM, 2004) |
| "The fondaparinux trials in venous thromboembolism (VTE) prevention after orthopaedic surgery have been subject to methodological criticisms recently summarised in this journal." | 4.82 | The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. ( Turpie, AG, 2004) |
| "Fondaparinux is a novel synthetic antithrombotic that has been evaluated for the prevention of venous thromboembolism (VTE)." | 4.82 | Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. ( Dranitsaris, G; Ginsberg, JS; Kahn, SR; Martineau, J; Paton, TW; Smith, R; Stumpo, C, 2004) |
| " In the outpatient treatment of venous thromboembolism, tinzaparin has demonstrated similar efficacy to dalteparin sodium (dalteparin) and warfarin." | 4.82 | Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. ( Cheer, SM; Dunn, CJ; Foster, R, 2004) |
| "To compare the cost-effectiveness of warfarin or enoxaparin with no prophylaxis for prevention of venous thromboembolism in patients undergoing total knee replacement (TKR) or knee arthroplasty." | 4.81 | Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. ( Martin, BC; Nerurkar, J; Wade, WE, 2002) |
| "The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer." | 4.02 | Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect? ( Alfonso, F; Alvarado-Casas, T; Rivero, F; Salamanca, J; Vera, A, 2021) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 3.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "Today, there is a small number of studies on the effects of Enoxaparin and Fondaparinux used commonly in the prevention of venous thromboembolism on healing of fracture cases." | 3.79 | Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats. ( Alabalik, U; Azboy, I; Bulut, M; Demirtas, A; Necmioglu, NS; Ucar, BY, 2013) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| " Pregnancy and fetal outcomes included miscarriage, stillbirth, baby death and live birth, small-for-gestational-age infants, warfarin embryopathy and warfarin-related fetal loss." | 3.75 | Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. ( McCowan, LM; McLintock, C; North, RA, 2009) |
| "The objective of this report is to describe the roles, responsibilities and recommendations of a 3-member Event Adjudication Committee (EAC) and a 5-member data monitoring committee (DMC) for a prospective multicenter observational study of critically ill patients with renal insufficiency examining the bioaccumulation and bleeding risk associated with dalteparin thromboprophylaxis." | 3.75 | Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis. ( Cook, D; Crowther, M; Douketis, J; Lee, A; Linkins, L; Marshall, JC; Meade, M; O'Donnell, M; Patel, R; Rabbat, C; Sinuff, T; Thabane, L; Treleaven, D; Zytaruk, N, 2009) |
| " This strategy may be associated with reduced risk of significant pocket hematoma compared with dalteparin bridging." | 3.75 | Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. ( Gula, LJ; Klein, GJ; Krahn, AD; Skanes, AC; Tischenko, A; Yee, R, 2009) |
| "Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism." | 3.73 | Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. ( Ahmed, M; Bragg, L; Brotman, DJ; Jaffer, AK; Klein, A; Qadeer, MA; Seshadri, N, 2005) |
| " In a similar patient population, the Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) trial evaluated the use of long-term dalteparin for the prevention of recurrent venous thromboembolism (VTE) in patients with cancer." | 3.73 | Selecting an anticoagulant for recurrent venous thromboembolism in cancer. ( Goodin, S, 2005) |
| "Fondaparinux did not inhibit osteoblast proliferation in vitro and may reduce the risk of heparin-induced osteoporosis associated with long-term heparin administration." | 3.73 | Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. ( Handschin, AE; Hoerstrup, SP; Kock, HJ; Trentz, O; Trentz, OA; Wanner, GA, 2005) |
| "We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients." | 3.73 | Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. ( Cohen, AT; Goldhaber, SZ; Kucher, N; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2005) |
| " The low-molecular-weight heparin dalteparin sodium is clinically effective in reducing the incidence of venous thromboembolism (VTE) in these patients." | 3.73 | Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. ( Heerey, A; Suri, S, 2005) |
| "To determine the rate of bleeding and thromboembolic events within 1 month of outpatient dalteparin therapy in veterans with mechanical heart valves, to evaluate potential risk factors associated with these events, and to examine the prescribing patterns of dalteparin in this patient population." | 3.73 | Safety of outpatient dalteparin therapy in veterans with mechanical heart valves. ( Copeland, LA; Flanagan, PS; O'Neill, JL; Zaleon, CR, 2005) |
| "In a recent randomised trial (CLOT [Comparison of Low molecular weight heparin versus Oral anticoagulant Therapy for long term anticoagulation in cancer patients with venous thromboembolism]), which evaluated secondary prophylaxis of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52% compared with oral anticoagulation therapy (p = 0." | 3.73 | Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. ( Crowther, M; Dranitsaris, G; Vincent, M, 2006) |
| "The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined." | 3.72 | The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. ( Borris, L; Bossuyt, P; de Pouvourville, G; Gordois, A; Jönsson, B; Levy, E; Posnett, J, 2003) |
| "Many orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty." | 3.72 | Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. ( Brotman, DJ; Hurbanek, JG; Jaffer, AK; Morra, N, 2004) |
| "Fondaparinux and enoxaparin are both effective and safe in preventing post-operative venous thromboembolism." | 3.72 | In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. ( Chakroun, T; Elalamy, I; Gerotziafas, GT; Samama, MM, 2004) |
| "Our study suggests that dalteparin may be used for the treatment of acute venous thromboembolism in pregnancy." | 3.72 | Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. ( Jacobsen, AF; Qvigstad, E; Sandset, PM, 2003) |
| " The initial treatment consisted of a 7-day course of subcutaneous dalteparin according to body weight." | 3.72 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 3.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ⩾35 (kg m(-2)) postcesarean delivery." | 2.82 | A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. ( Caballero, DC; McNulty, J; Neeper, JM; Serra, AE; Stephenson, ML, 2016) |
| "Advanced pancreatic cancer (APC), beside its high mortality, causes the highest rates of venous thromboembolic events (VTE)." | 2.79 | Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. ( Bahra, M; Dörken, B; Gebauer, B; Hilbig, A; Pelzer, U; Riess, H; Sinn, M; Stieler, JM, 2014) |
| "Edoxaban is an oral, direct, once-daily factor Xa inhibitor." | 2.79 | Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. ( Abe, K; Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Kiuchi, Y; Nakamura, M; Tachibana, S, 2014) |
| " Safety endpoints included the incidence of major bleeding, clinically relevant non-major (CRNM) bleeding, major bleeding or CRNM bleeding, all bleeding events, adverse events, and adverse drug reactions." | 2.79 | Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. ( Abe, K; Fuji, T; Fujita, S; Ibusuki, K; Kawai, Y; Kimura, T; Nakamura, M; Tachibana, S; Ushida, H; Wang, CJ, 2014) |
| " The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious." | 2.78 | Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury. ( Barnes, SL; Farooqui, A; Hiser, B; Litofsky, NS, 2013) |
| "2 U/mL, is safe for women with mechanical prosthetic heart valves (MPHV)." | 2.76 | A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. ( Aziz, RH; Dominique, TG; Jacobson, BF; Pravin, M; Saeed, CR; Serasheini, M, 2011) |
| "Major bleeding was comparable and minor bleedings (0." | 2.76 | Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. ( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011) |
| " There is a lack of consensus in guidelines regarding the timing of administration and the dosage of thromboprophylactic agents." | 2.75 | Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. ( Attaran, S; Awad, WI; Somov, P, 2010) |
| "A population pharmacokinetic model was developed using anti-factor (F)Xa activity data from 126 children (median age: 5." | 2.75 | Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ( Hempel, G; Krümpel, A; Male, C; Mitchell, L; Nowak-Göttl, U; Trame, MN, 2010) |
| " It is a hydrophilic molecule that is, predominantly, eliminated renally with few data to support dosing for subjects with renal impairment and/or obesity." | 2.75 | Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2010) |
| " The betrixaban dosage was blinded, but enoxaparin was not." | 2.74 | A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). ( Bauer, KA; Davidson, BL; Fisher, WD; Gent, M; Gretler, DD; Huo, MH; Sinha, U; Turpie, AG, 2009) |
| " Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study." | 2.74 | How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. ( Hammerstingl, C; Omran, H; Poetzsch, B; Tripp, C, 2009) |
| "Data were obtained from a randomized controlled trial (n = 118) that compared conventional dosing of enoxaparin (product label) with an individualized dosing regimen." | 2.74 | Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2009) |
| "Dalteparin was injected s." | 2.74 | Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. ( Brodmann, D; Fischer, AG; Schmid, P; Wuillemin, WA, 2009) |
| "The risk of venous thromboembolism is equally high in medical patients admitted to the hospital and those treated in the surgery wards." | 2.73 | [Two models of thromboprophylaxis in acutely ill medical inpatients]. ( Firek, A; Kochanowski, Z; Luba, M, 2007) |
| " As this accumulation depends on heparin chain length and subsequent reticulo-endothelial/renal elimination, LMWHs might have different pharmacodynamic profiles." | 2.73 | Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. ( Aghassarian, M; Bal Dit-Sollier, C; Bergmann, JF; Drouet, L; Heilmann, JJ; Lacut, K; Mahé, I; Mottier, D, 2007) |
| "Internal carotid artery stenosis was asymptomatic in 55% and symptomatic in 45%." | 2.73 | Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. ( Assadian, A; Hagmüller, GW; Hübl, W; Klingler, A; Knöbl, P; Pfaffelmeyer, N; Senekowitsch, C, 2008) |
| "The optimal thromboprophylactic dosage regimen of low-molecular-weight heparins in high-risk general surgery remains debatable." | 2.72 | A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. ( Bergman, JF; Derlon, A; Laporte, S; Mismetti, P; Samama, CM; Samii, K; Simonneau, G, 2006) |
| "Search terms included "Lemierre Syndrome" AND "anticoagulation" NOT "prophylaxis" OR "atrial fibrillation," in addition to a list of parenteral and oral anticoagulants." | 2.72 | Anticoagulation Strategies in the Management of Lemierre Syndrome: A Systematic Review of the Literature. ( Adedeji, A; Chukwura, O; McNulty, SB; Obafemi, T; Reinert, JP, 2021) |
| " The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939." | 2.72 | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. ( Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F, 2006) |
| "Aspirin was started on the day of surgery, whereas enoxaparin was started 48 hours after surgery." | 2.72 | VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. ( Bottner, F; Haas, SB; Laskin, RS; Sculco, TP; Westrich, GH; Windsor, RE, 2006) |
| "Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis." | 2.72 | Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. ( Brom, J; Csányi, A; Diener, HC; Harenberg, J; Klingelhöfer, J; Koppenhagen, K; Landgraf, H; Rektor, I; Ringelstein, EB; Schneider, D; von Kummer, R; Weidinger, G, 2006) |
| "Dalteparin was demonstrated to be safe over 16 weeks of treatment in these patients." | 2.72 | Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. ( Abecasis, NG; Baronius, W; Biakhov, M; Fountzilas, G; Garin, A; Giorgetti, C; Irwin, D; Karthaus, M; Kretzschmar, A; Kröning, H; Marschner, N; Reichardt, P; Slabber, C; Steger, GG; Südhoff, T, 2006) |
| "Pulmonary embolism was discovered at autopsy in 10 of 63 patients in the nadroparin group and in 17 of 60 in the placebo group [relative risk reduction 0." | 2.71 | Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. ( Bergmann, JF; Caulin, C; d'Azémar, P; Mahé, I; Vaissie, JJ, 2005) |
| " This trial shows that bemiparin started postoperatively is as effective and safe as enoxaparin started preoperatively in the prevention of venous thromboembolism in patients undergoing total knee replacement." | 2.71 | Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. ( Castellet, E; Navarro-Quilis, A; Paz-Jiménez, J; Planès, A; Rocha, E, 2003) |
| "The risk of venous thromboembolism is high after spinal cord injury (SCI)." | 2.71 | Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. ( , 2003) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 2.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 2.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| "Patients were screened for deep vein thrombosis by sonography every week." | 2.71 | Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. ( Becker, C; Bodamer, I; Brom, J; Eisele, RR; Galster, H; Grambach, K; Kolb, G; Koudela, K; Paal, V; Seidlmayer, C; Spannagel, U; Weidinger, G, 2003) |
| " Both population pharmacokinetic analysis using nonlinear mixed-effect modeling techniques and model-independent pharmacokinetic methods were employed." | 2.71 | Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. ( Chan, A; Dinyari, M; Kuhle, S; Marzinotto, V; Massicotte, P; Mitchell, D; Mitchell, LG; Pieniaszek, H; Vegh, P, 2005) |
| "DUSG showed deep venous thrombosis (DVT) on the 7th postoperative day in 10 patients in Group 1, in 8 patients in Group 2 and in 3 patients in Group 3." | 2.70 | [Thromboembolic prophylaxis after major abdominal surgery]. ( Adigüzel, H; Balik, AA; Başoğlu, M; Celebi, F; Oren, D; Yildirgan, MI, 2001) |
| " In morbidity obese patients, the limited number of comparative trials are too sparse to allow a consensus on the effective dose and dosing schedule." | 2.70 | Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. ( Dimitrakopoulos, A; Kalfarentzos, F; Karamesini, M; Kehagias, I; Maniati, A; Stavropoulou, F; Yarmenitis, S, 2001) |
| "Deep vein thrombosis was assessed by routine bilateral contrast venography performed between postoperative day 5 and 9, or earlier if clinically suspected." | 2.70 | Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. ( Anderson, DR; Atkinson, KG; Barton, P; Burnstein, M; Burul, CJ; Geerts, WH; Greenwood, C; Gregoire, RC; Marshall, JC; McLeod, RS; Ross, T; Silverman, RE; Sniderman, KW; Taylor, BM; Wilson, SR, 2001) |
| "Venous thromboembolism is a frequent complication of total hip replacement." | 2.70 | A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. ( Gallus, AS; Hoek, JA; Turpie, AG, 2001) |
| "Forty-one consecutive children with acute lymphoblastic leukemia (ALL) received prophylaxis therapy with the low molecular weight heparin (LMWH) enoxaparin during L-asparaginase treatment." | 2.70 | Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. ( Ben Barak, A; Brenner, B; Elhasid, R; Lanir, N; Levin, C; Postovsky, S; Sharon, R; Weyl Ben Arush, M, 2001) |
| "Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition." | 2.70 | Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001) |
| " We did a multicentre, randomised, double-blind study to examine the dose-response relation of subcutaneous melagatran, a direct thrombin inhibitor, followed by oral ximelagatran as thromboprophylaxis after total hip or knee replacement." | 2.70 | Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. ( Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L, 2002) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 2.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| " The study did not evaluate a dose-response for efficacy, and no differences between the three dose levels of melagatran and ximelagatran were shown." | 2.70 | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002) |
| "This pharmacodynamic study examined weight-based dosing of the low molecular weight heparin (LMWH), tinzaparin, in heavyweight/obese subjects." | 2.70 | Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Leathers, T; Leese, PT, 2002) |
| "Dalteparin or dextran was used during delivery." | 2.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| " However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use." | 2.68 | A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. ( Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J, 1996) |
| "Distal and proximal thrombosis, pulmonary embolism, and hemorrhage were also recorded, as were deaths." | 2.68 | Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. ( Benoni, G; Bergqvist, D; Björgell, O; Fredin, H; Hedlundh, U; Nicolas, S; Nilsson, P; Nylander, G, 1996) |
| "Enoxaparin, 40 mg once daily, is as safe and effective as unfractionated heparin three times daily in preventing venous thromboembolism in patients undergoing major elective surgery for abdominal or pelvic malignancy." | 2.68 | Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. ( , 1997) |
| "One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb." | 2.68 | A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. ( Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Luomanmäki, K; Sörskog, L; Vilkko, P, 1996) |
| "The naproxen was given orally (500 mg as a single daily dose, n = 39)." | 2.67 | [Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent]. ( Auger, D; Grange, P; Hecquet, JP; Remond, A; Titon, JP; Ulliac, P; Vaissié, JJ, 1994) |
| " We used American College of Obstetrics and Gynecology recommendations as the base for screening and dosing guidelines and utilized known and published absolute risk values and odds ratios to stratify risk factors." | 2.61 | Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines. ( Deering, SH; Eubanks, AA; Thiel, LM, 2019) |
| " Areas covered: We have not found noticeable differences between Brazilian biosimilar enoxaparins and the original product regarding their physicochemical properties, disaccharide composition, anticoagulant activity, bioavailability and safety." | 2.53 | Update on Brazilian biosimilar enoxaparins. ( Glauser, BF; Mourão, PA; Oliveira, SM; Tovar, AM; Vilanova, E, 2016) |
| " Furthermore, there is no difference according to liver enzymes elevation and cardio-vascular adverse events." | 2.44 | [Rivaroxaban (Xarelto): efficacy and safety]. ( Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N, 2008) |
| " Further investigations as a basis of general recommendations on standard dosing regimen are outstanding for use of each LMWH in percutaneous coronary interventions, as combination with Glycoprotein IIb/IIIa-inhibitors, in acute myocardial infarction and in artificial heart valves." | 2.42 | Anticoagulation with low-molecular-weight heparin in patients with heart diseases. ( Bechtold, H; Janssen, D, 2004) |
| "Venous thromboembolism is a multifactorial silent disease and tends not to be suspected by physicians, especially in medical patients." | 2.42 | Prophylaxis of venous thromboembolism in medical patients. ( Gerotziafas, GT; Samama, MM, 2004) |
| "Fondaparinux was superior to enoxaparin 40 mg once/day in the setting of hip fracture surgery, with no increased risk of major bleeding." | 2.42 | Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data. ( Lobo, BL, 2004) |
| "Fondaparinux was also used, with promising results, in prophylaxis in patients undergoing major abdominal surgery and high risk medical patients." | 2.42 | Pentasaccharides. The new anticoagulants. ( Abdel-Razeq, H, 2004) |
| " Various clinical studies in unstable angina and acute coronary syndrome have proved that clivarine in a dosage of 3436anti-Xa units twice daily is an effective antithrombotic agent." | 2.42 | Reviparin sodium clivarine: a review of its therapeutic use. ( Gore, M; Kelkar, P; Rege, N; Ross, C, 2004) |
| " The dosage of LMWH was performed by body weight adjustment without dose-finding studies." | 2.42 | [Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]. ( Harenberg, J, 2003) |
| "Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of approximately 5,000." | 2.42 | Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. ( Hull, RD; Pineo, GF, 2004) |
| "Fondaparinux also appears to be a very promising candidate for the treatment of patients with existing VTE." | 2.41 | Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2002) |
| "Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation." | 2.41 | Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. ( Doggrell, SA, 2002) |
| " As prophylaxis, reviparin 1,750 anti-XaIU once daily was as effective as unfractionated heparin 5,000IU twice daily in 1,311 patients undergoing abdominal surgery and, in a once daily dosage of 4,200 anti-XaIU, was as effective as subcutaneous enoxaparin sodium 40 mg/day or acenocoumarol in patients undergoing hip replacement surgery." | 2.41 | Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. ( Jarvis, B; McClellan, K; Wellington, K, 2001) |
| "Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of 5000." | 2.41 | Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. ( Dunn, CJ; Jarvis, B, 2000) |
| " Compared with unfractionated heparin (UFH), nadroparin has a greater ratio of anti-factor Xa to anti-factor Ha activity, greater bioavailability and a longer duration of action, allowing it to be administered by subcutaneous injection for prophylaxis or treatment of thromboembolic disorders." | 2.40 | Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. ( Davis, R; Faulds, D, 1997) |
| " Moreover, subcutaneous parnaparin has a greater bioavailability and longer half-life than heparin, permitting once-daily administration for the prophylaxis of deep venous thrombosis (DVT) or the treatment of established vascular disorders." | 2.39 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. ( Faulds, D; Frampton, JE, 1994) |
| " In comparative clinical trials, this dosage demonstrated either improved efficacy and a similar haemorrhagic profile, or a similar degree of efficacy with a lower rate of haemorrhagic events, compared with unfractionated heparin 5000IU 3 times daily." | 2.39 | Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. ( Goa, KL; Noble, S; Peters, DH, 1995) |
| " The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible." | 2.39 | Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994) |
| " Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence." | 2.39 | Contemporary use of and future roles for heparin in antithrombotic therapy. ( Gibaldi, M; Wittkowsky, AK, 1995) |
| "Dalteparin sodium has also shown clinical benefit in the management of patients with unstable angina or non-Q-wave myocardial infarction." | 2.39 | Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. ( Dunn, CJ; Sorkin, EM, 1996) |
| "5 kD, has greater bioavailability and a longer duration of action than unfractionated heparin, allowing it to be administered once daily by subcutaneous injection for both prophylaxis and treatment of deep venous thrombosis (DVT)." | 2.39 | Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. ( Balfour, JA; Friedel, HA, 1994) |
| " In hemodialysis patients, enoxaparin at once daily reduced dosing should be considered with trough and peak anti-Xa levels monitoring." | 1.62 | Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms. ( Bahabri, A; Belostosky, V; Bhatt, MD; Chan, AKC, 2021) |
| " Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown." | 1.62 | Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. ( Aimaretti, G; Avanzi, GC; Azzolina, D; Bellan, M; Cantaluppi, V; Capponi, A; Castello, LM; Cipollone, F; Colombo, C; Corte, FD; D'Ardes, D; Foglietta, M; Gallina, S; Grisafi, L; Hayden, E; Krengli, M; Lio, V; Malerba, M; Mennuni, MG; Patti, G; Petrilli, I; Pierdomenico, SD; Pirisi, M; Renda, G; Rognoni, A; Sainaghi, PP; Savoia, P; Spinoni, E; Zeppegno, P, 2021) |
| "Major bleeding was defined by INTERMACS criteria." | 1.62 | Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients. ( Ahuja, T; Arnouk, S; Gidea, C; Lewis, TC; Moazami, N; Papadopoulos, J; Patel, M; Reyentovich, A; Smith, DE, 2021) |
| "Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment." | 1.56 | Thromboembolic and bleeding complications in patients with oesophageal cancer. ( Büller, HR; Hovenkamp, A; Hulshof, MCCM; Kamphuisen, PW; Middeldorp, S; Mulder, FI; van Berge Henegouwen, MI; van Es, N; van Laarhoven, HWM, 2020) |
| " Real-time enoxaparin dose adjustment significantly increased the proportion of patients who achieved in-range peak aFXa levels, compared to standard dosing (74." | 1.48 | Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose. ( Fleming, KI; Lonardo, N; Nirula, R; Nunez, J; Pannucci, CJ; Shipley, RW; Tonna, JE; Wall, V, 2018) |
| " Population pharmacokinetic analysis was performed with bootstrap analysis." | 1.48 | Population Pharmacokinetics of Enoxaparin in Pediatric Patients. ( Galati, M; Lee-Kim, Y; Mahoney, D; Moffett, BS; Shah, MD; Teruya, J; Yee, D, 2018) |
| "Our study suggests that anticoagulation with IV enoxaparin infused over 30 minutes is a safe and an equally effective alternative to subcutaneous enoxaparin in critically ill infants and children." | 1.46 | IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes. ( Alfares, FA; Berger, JT; Chounoune, R; Corcoran, J; Diab, YA; Endicott, KM; Ferrell, B; Nath, DS; Ramakrishnan, K; Rooney, S; Shankar, V; Zurakowski, D, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 1.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "These findings suggest that vertebral compression fractures and PPO may be one of the causes of severe back pain in postpartum patients." | 1.42 | Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. ( Cakir, B; Dirikoc, A; Ersoy, R; Ozdemir, D; Tam, AA, 2015) |
| " Protocols vary from center to center, but there is still no consensus regarding the proper dosage or treatment duration." | 1.42 | The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism. ( Caner, İ; Demirelli, Y; Kara, M; Tekgündüz, KŞ, 2015) |
| "Enoxaparin sodium has predictable pharmacokinetics that allow for simplified dosing without laboratory monitoring." | 1.38 | Enoxaparin outcomes in patients with moderate renal impairment. ( Clairmont, MA; DeCarolis, DD; Johnson, GJ; Leuthner, AM; Rector, TS; Thorson, JG, 2012) |
| "Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF)." | 1.37 | Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. ( Alberti, S; Angeloni, G; Banzato, A; Cucchini, U; Formichi, M; Pengo, V; Romagnoli, E, 2011) |
| "He was initially diagnosed with a pulmonary thromboembolism." | 1.37 | Metastatic osteosarcoma presenting as a single pulmonary microembolus. ( Chin, C; Midulla, P; Shapiro, M; Wistinghausen, B, 2011) |
| "Thromboembolism is treated with a weight-adjusted enoxaparin dose without the need for laboratory monitoring." | 1.37 | Non-therapeutic anti-FXa levels are common among medical ward patients treated with enoxaparin. ( Elias, M; Goldstein, L; Lavi, I; Nitzan, O; Rock, W; Ron, G; Saliba, W; Zalman, L, 2011) |
| "Rivaroxaban has been recommended for routine use as a thromboprophylactic agent in patients undergoing lower-limb arthroplasty." | 1.37 | Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. ( Jensen, CD; Muller, SD; Partington, PF; Reed, MR; Steval, A, 2011) |
| "Preoperatively, patients discontinued VKA for 5 +/- 1 days; in those at low risk for thrombosis, LMWH was given at a prophylactic dosage of 3800 UI (nadroparin) or 4000 UI (enoxaparin) anti-factor (F) Xa once daily the night before the procedure." | 1.36 | Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. ( Abbene, I; Caramazza, D; Casuccio, A; Lo Coco, L; Malato, A; Pizzo, G; Saccullo, G; Siragusa, S, 2010) |
| " This study was designed to determine whether paediatric-specific dosage requirements for LMWH are justified, by investigating the doses required to achieve target therapeutic ranges." | 1.36 | Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children. ( Ignjatovic, V; Monagle, P; Najid, S; Newall, F; Summerhayes, R, 2010) |
| "In patients receiving oral anticoagulant therapy with a target INR of 2,0-3,0 and at an intermediate risk of thromboembolic events who require interruption of oral anticoagulant therapy a half therapeutic dose of enoxaparin seems to be safe and effective for bridging." | 1.36 | Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy. ( Essers, E; Gottstein, S; Klamroth, R; Landgraf, H, 2010) |
| "Enoxaparin significantly decreased deep venous thrombosis risk in patients undergoing circumferential abdominoplasty." | 1.35 | Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery. ( Abtahi, F; Brown, SA; Farkas, JP; Hatef, DA; Kenkel, JM; Nguyen, MQ; Rohrich, RJ, 2008) |
| " While patients with renal impairment have a higher risk of bleeding and dosing of heparins is more difficult, there are no specific recommendations for bridging the latter patients." | 1.35 | Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. ( Hammerstingl, C; Omran, H, 2009) |
| "We present three cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel." | 1.35 | Air travel and pulmonary embolism: "economy class syndrome". ( Arora, P; Bhatia, V; Kaul, U; Mittal, A; Pandey, AK; Parida, AK, 2009) |
| "But dabigatran was associated with surgical wound seepage in 7% of patients, versus 4." | 1.35 | Dabigatran: new drug. Continue to use heparin, a better-known option. ( , 2009) |
| "No proximal deep venous thrombosis or other thromboembolic events occurred." | 1.34 | Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. ( Bugamelli, S; Calò, P; Ferrari, P; Montebugnoli, M; Zangheri, E, 2007) |
| "Many cancer patients are still poorly assessed for risk of VTE." | 1.34 | Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. ( Altimiras, J; Balibrea, JL; Gómez-Outes, A; Larruzea, I; Martínez-González, J; Rocha, E, 2007) |
| " Dosing history and measurements of anti-Xa activity in sparse samples were recorded throughout treatment." | 1.34 | Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. ( Alamartine, E; Berges, A; Decousus, H; Epinat, M; Laporte, S; Mismetti, P; Tranchand, B; Zufferey, P, 2007) |
| " In 35 patients (34%) with renal impairment (creatinine clearance <50 ml/min), LMWH dosage was halved." | 1.34 | Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. ( Hammerstingl, C; Omran, H; Schmidt, H; Tripp, C; von der Recke, G, 2007) |
| "The incidence of deep venous thrombosis in both cohorts was 0." | 1.34 | Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. ( Kothari, SN; Lambert, PJ; Mathiason, MA, 2007) |
| "Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
| "Once-daily dosing of prophylactic LMWH dalteparin is feasible, safe, and effective in high-risk trauma patients." | 1.34 | Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients. ( Cothren, CC; Moore, EE; Morgan, SJ; Smith, WR, 2007) |
| "Melagatran did not increase the risk of thromboembolism or bleeding." | 1.34 | Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model. ( Hamner, CE; Lewin, M; Potter, DD; Schaff, HV; Sundt, TM; Thompson, JL, 2007) |
| "When a hematoma is large, the initial clinical picture may include hypovolemic shock, which may develop during surgery if the hematoma is not diagnosed early." | 1.33 | [Hypovolemic shock during surgery caused by a rectus sheath hematoma]. ( García, R; López-Escobar, M; Medina, C; Torres, LM; Vidal, MA, 2005) |
| "Fondaparinux sodium is a new antithrombotic agent that is indicated for prophylaxis of VTE after major orthopedic surgery." | 1.33 | Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. ( Bjorvatn, A; Kristiansen, F, 2005) |
| "In patients with malignant tumors not only the incidence of VTE is higher but the course of VTE is more severe and relapses are more frequent." | 1.33 | [Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study]. ( Farkas, E; Köves, I; Mátrai, Z; Péley, G; Rényi-Vámos, F, 2005) |
| "Inherited thrombophilia is associated with thromboembolic events and/or poor obstetric outcome." | 1.33 | Inherited thrombophilia: treatment during pregnancy. ( Caruso, A; De Carolis, S; De Stefano, V; Fatigante, G; Ferrazzani, S; Garofalo, S; Leone, G; Rossi, E, 2006) |
| " Clexane was also used for thromboembolic complications prophylaxis during performance of operative intervention (in 40 mg daily dosage during 7-12 days)." | 1.33 | [Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer]. ( Sukhoversha, OA, 2006) |
| "To develop an appropriate dosing strategy for continuous intravenous infusions (CII) of enoxaparin by minimizing the percentage of steady-state anti-Xa concentration (C(ss)) outside the therapeutic range of 0." | 1.33 | Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. ( Bies, RR; Bobek, MB; Duffull, SB; Feng, Y; Green, B; Kane-Gill, SL, 2006) |
| "Subchorionic hematoma is a potentially serious complication that can occur in pregnant patients receiving enoxaparin for the prevention of thromboembolism." | 1.33 | Massive subchorionic hematoma associated with enoxaparin. ( Goodwin, TM; Lee, RH, 2006) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 1.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| "epigastrica superficialis." | 1.32 | [Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report]. ( Andereya, S; Buschmeier, M; Hopf, KF; Kälicke, T; Muhr, G, 2003) |
| "Venous thromboembolism was previously regarded as a surgical problem, but occurs at least as frequently among medical patients." | 1.32 | Venous thromboembolic risk and prevention in acute medical illness. ( Hampton, KK, 2003) |
| "Enoxaparin seems to offer safe and effective procedural anticoagulation in patients undergoing percutaneous intervention for acute coronary syndromes." | 1.32 | Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes? ( Ayzenberg, Y; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2004) |
| " The drugs are marked by bioavailability approximating 100%, linear dose-dependent pharmacokinetic profile at subcutaneous injection; they do not undergo metabolism and are excreted largely with urine." | 1.32 | [Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)]. ( Averkov, OV, 2004) |
| " Today we know that the real advantage of LMWHs is due to their high bioavailability which makes safe and reliable their subcutaneous administration without laboratory monitoring." | 1.31 | [State of the art: low-molecular-weight heparin and beyond]. ( Casali, G; Cimminiello, C; Vitali, L, 2000) |
| "Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH)." | 1.31 | Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. ( Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM, 2001) |
| "Incidence, seriousness and causality of maternal, fetal and neonatal adverse events, pregnancy outcome, and incidence of venous thromboembolism." | 1.31 | Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. ( Borel-Derlon, A; Borg, JY; Boudignat, O; Cohen, C; Conard, J; Darmon, JY; Francoual, C; Lepercq, J; Priollet, P; Schved, JF; Tournaire, M; Yvelin, N, 2001) |
| " All patients received enoxaparin at a dosage of 100 IU antiXa/kg twice daily before undergoing multiplane TEE." | 1.31 | A new therapeutic strategy for electrical cardioversion of atrial fibrillation. ( de Luca, I; de Luca, L; Del Salvatore, B; Sorino, M, 2001) |
| "Outpatient treatment of acute proximal deep vein thrombosis with enoxaparin has also been shown to be cost effective compared with inpatient treatment using UFH." | 1.31 | Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. ( Bergqvist, D, 2002) |
| "A deep vein thrombosis was identified in 2 (2%) of 106 patients." | 1.31 | Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. ( Berne, JD; Grahm, TW; Kerns, DB; McAuley, CE; McLarty, JW; Norwood, SH; Short, K; Vallina, VL, 2002) |
| " One daily dosage of 5,000 IU anti-Xa resulted in a measurable level of FXa for 24 h in pregnancy week 40, compared with 17h at pregnancy week 37." | 1.31 | Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. ( Blombäck, M; Bremme, K; van Rooijen, M; Yu, A, 2001) |
| "Pretreatment with aspirin and/or fraxiparine in the presence of ionic contrast media showed antithrombotic activities equal to those obtained when they were tested alone (p<0." | 1.30 | Aspirin and fraxiparine in the prevention of laser induced thrombosis in the presence of iodinated contrast media. ( Aguejouf, O; Belougne Malfatti, E; Doutremepuich, C; Doutremepuich, F, 1998) |
| "Three patients (0." | 1.30 | The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. ( Geerts, WH; Gent, M; Ginsberg, JS; Hirsh, J; Leclerc, JR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 90 (18.07) | 18.2507 |
| 2000's | 294 (59.04) | 29.6817 |
| 2010's | 98 (19.68) | 24.3611 |
| 2020's | 16 (3.21) | 2.80 |
| Authors | Studies |
|---|---|
| Mulder, FI | 1 |
| Hovenkamp, A | 1 |
| van Laarhoven, HWM | 1 |
| Büller, HR | 4 |
| Kamphuisen, PW | 1 |
| Hulshof, MCCM | 1 |
| van Berge Henegouwen, MI | 1 |
| Middeldorp, S | 1 |
| van Es, N | 1 |
| Duzhyĭ, ID | 1 |
| Kravets', OV | 1 |
| Hres'ko, IIa | 1 |
| Iurchenko, AV | 1 |
| Schindewolf, M | 1 |
| Recke, A | 1 |
| Zillikens, D | 1 |
| Lindhoff-Last, E | 1 |
| Ludwig, RJ | 1 |
| Fricker, J | 1 |
| Bajkin, BV | 1 |
| Popovic, SL | 1 |
| Selakovic, SD | 1 |
| Agnelli, G | 7 |
| Gussoni, G | 1 |
| Bianchini, C | 2 |
| Verso, M | 2 |
| Mandalà, M | 2 |
| Cavanna, L | 1 |
| Barni, S | 2 |
| Labianca, R | 2 |
| Buzzi, F | 1 |
| Scambia, G | 1 |
| Passalacqua, R | 1 |
| Ricci, S | 1 |
| Gasparini, G | 2 |
| Lorusso, V | 1 |
| Bonizzoni, E | 2 |
| Tonato, M | 1 |
| Noble, S | 2 |
| Malato, A | 1 |
| Saccullo, G | 1 |
| Lo Coco, L | 1 |
| Caramazza, D | 1 |
| Abbene, I | 1 |
| Pizzo, G | 1 |
| Casuccio, A | 1 |
| Siragusa, S | 1 |
| Galimov, OV | 1 |
| Galeev, FS | 1 |
| Khanov, VO | 1 |
| Mukhametov, AR | 1 |
| Andreev, PP | 1 |
| Muslimova, LR | 1 |
| Aminova, LN | 1 |
| Brighenti, M | 1 |
| Petrelli, F | 1 |
| Perrone, T | 1 |
| Snijder, CA | 1 |
| Cornette, JM | 1 |
| Hop, WC | 1 |
| Kruip, MJ | 1 |
| Duvekot, JJ | 1 |
| Say, F | 1 |
| Iltar, S | 1 |
| Alemdaroğlu, KB | 1 |
| Ozel, I | 1 |
| Aydoğan, NH | 1 |
| Gönültaş, M | 1 |
| Reznikov, AV | 1 |
| Driuk, NF | 1 |
| Iaremchuk, AIa | 1 |
| Zotov, AS | 1 |
| Cheshuk, VE | 1 |
| Anikuc'ko, NF | 1 |
| Zakhartseva, LM | 1 |
| Diatel, MV | 1 |
| Kravchenko, AV | 1 |
| Lobanova, OE | 1 |
| Sidorchuk, OI | 1 |
| Orlovskiĭ, PI | 1 |
| Gritsenko, VV | 1 |
| Vavilova, TV | 1 |
| Kadinskaia, MI | 1 |
| Petrishina, TI | 1 |
| Mochalov, OIu | 1 |
| Polezhaev, DA | 1 |
| Galileeva, AN | 1 |
| Mahé, I | 4 |
| Bergmann, JF | 3 |
| d'Azémar, P | 1 |
| Vaissie, JJ | 2 |
| Caulin, C | 1 |
| Bergqvist, D | 7 |
| Vidal, MA | 1 |
| López-Escobar, M | 1 |
| Medina, C | 1 |
| García, R | 1 |
| Torres, LM | 1 |
| Simonneau, G | 3 |
| Laporte, S | 3 |
| Mismetti, P | 4 |
| Derlon, A | 1 |
| Samii, K | 1 |
| Samama, CM | 1 |
| Bergman, JF | 1 |
| Tosetto, A | 1 |
| Kosior, DA | 1 |
| Torbicki, A | 1 |
| Opolski, G | 1 |
| Luba, M | 1 |
| Firek, A | 1 |
| Kochanowski, Z | 1 |
| O'Meara, AC | 1 |
| Demarmels Biasiutti, F | 1 |
| Heizmann, M | 1 |
| Potter, J | 1 |
| Lavrik, AS | 2 |
| Tyvonchuk, AS | 2 |
| Bubalo, AF | 2 |
| Zgonnik, AIu | 1 |
| Collignon, F | 1 |
| Frydman, A | 1 |
| Caplain, H | 1 |
| Ozoux, ML | 1 |
| Le Roux, Y | 1 |
| Bouthier, J | 1 |
| Thébault, JJ | 1 |
| Holland, K | 1 |
| Schain, FH | 1 |
| Forette, B | 1 |
| Wolmark, Y | 1 |
| Titon, JP | 1 |
| Auger, D | 1 |
| Grange, P | 1 |
| Hecquet, JP | 1 |
| Remond, A | 1 |
| Ulliac, P | 1 |
| Doganov, N | 1 |
| Iarŭkov, A | 1 |
| Mladenova, A | 1 |
| Doncheva, O | 1 |
| Ogoĭska, I | 1 |
| Barkagan, ZS | 1 |
| Koopman, MM | 1 |
| Prandoni, P | 3 |
| Piovella, F | 4 |
| Ockelford, PA | 1 |
| Brandjes, DP | 1 |
| van der Meer, J | 1 |
| Gallus, AS | 3 |
| Chesterman, CH | 1 |
| Prins, MH | 3 |
| Hirsh, J | 6 |
| Saenko, VF | 1 |
| Viktorov, AP | 1 |
| Golopykho, LI | 1 |
| Mabilia, MA | 1 |
| Minicucci, S | 1 |
| Pettiti, G | 1 |
| Tamponi, G | 1 |
| Bogli, F | 1 |
| Davis, R | 1 |
| Faulds, D | 3 |
| Talley, JD | 1 |
| Llau, JV | 1 |
| Hoyas, L | 1 |
| Ezpeleta, J | 1 |
| García-Polit, J | 1 |
| Canova, CR | 1 |
| Fischler, MP | 1 |
| Reinhart, WH | 1 |
| Czestochowska, E | 2 |
| Arasimowicz, P | 1 |
| Yoo, MC | 1 |
| Kang, CS | 1 |
| Kim, YH | 1 |
| Kim, SK | 1 |
| Aguejouf, O | 1 |
| Belougne Malfatti, E | 1 |
| Doutremepuich, F | 1 |
| Doutremepuich, C | 1 |
| Martyin, T | 1 |
| Jakucs, J | 1 |
| Iványi, J | 1 |
| Kis, E | 1 |
| Varga, I | 1 |
| Mellár, E | 1 |
| Tam, WH | 1 |
| Wong, KS | 1 |
| Yuen, PM | 1 |
| Leung, TN | 1 |
| Li, CY | 1 |
| Pottier, P | 1 |
| Planchon, B | 1 |
| Truchaud, F | 1 |
| Pistorius, MA | 1 |
| Furic, I | 1 |
| Grolleau, JY | 1 |
| Cimminiello, C | 4 |
| Casali, G | 1 |
| Vitali, L | 1 |
| Grau, E | 1 |
| Tenias, JM | 1 |
| Real, E | 1 |
| Medrano, J | 1 |
| Ferrer, R | 1 |
| Pastor, E | 1 |
| Selfa, S | 1 |
| Jiménez Martín, CM | 1 |
| Durán Quintana, JA | 1 |
| Abadín Delgado, JA | 1 |
| Cruz Fernández, JM | 1 |
| Sánchez Romero, A | 1 |
| Hofmann, S | 1 |
| Knoefler, R | 1 |
| Lorenz, N | 1 |
| Siegert, G | 1 |
| Wendisch, J | 1 |
| Mueller, D | 1 |
| Taut-Sack, H | 1 |
| Dinger, J | 1 |
| Kabus, M | 1 |
| Couturaud, F | 1 |
| Julian, JA | 4 |
| Kearon, C | 4 |
| Nichitaĭlo, ME | 1 |
| Beliaev, VV | 1 |
| Celebi, F | 1 |
| Balik, AA | 1 |
| Yildirgan, MI | 1 |
| Başoğlu, M | 1 |
| Adigüzel, H | 1 |
| Oren, D | 1 |
| Kalfarentzos, F | 1 |
| Stavropoulou, F | 1 |
| Yarmenitis, S | 1 |
| Kehagias, I | 1 |
| Karamesini, M | 1 |
| Dimitrakopoulos, A | 1 |
| Maniati, A | 1 |
| Angeloni, G | 1 |
| Alberti, S | 1 |
| Romagnoli, E | 1 |
| Banzato, A | 1 |
| Formichi, M | 1 |
| Cucchini, U | 1 |
| Pengo, V | 1 |
| Montebugnoli, M | 1 |
| Bugamelli, S | 1 |
| Calò, P | 1 |
| Zangheri, E | 1 |
| Ferrari, P | 1 |
| Frampton, JE | 1 |
| Gioè, FP | 1 |
| Arcara, M | 1 |
| Scaffidi Abbate, F | 1 |
| Mercadante, T | 1 |
| Pietrelli, F | 1 |
| Renzoni, T | 1 |
| Cicoli, C | 1 |
| Sagüillo, K | 1 |
| Pérez-Flecha, F | 1 |
| Almeida, F | 1 |
| Picón, M | 1 |
| Acero, J | 1 |
| Calderero Aragón, V | 1 |
| de Gregorio Ariza, MA | 1 |
| Pazo Cid, R | 1 |
| Puértolas Hernández, T | 1 |
| Lostalé Latorre, F | 1 |
| Artal Cortés, A | 1 |
| Antón Torres, A | 1 |
| Navarro-Quilis, A | 2 |
| Castellet, E | 1 |
| Rocha, E | 5 |
| Paz-Jiménez, J | 1 |
| Planès, A | 6 |
| Honorato, J | 1 |
| Gómez-Outes, A | 2 |
| Martínez-González, J | 2 |
| Modesto-Alapont, M | 1 |
| Nauffal-Manzur, D | 1 |
| Ansótegui-Barrera, E | 1 |
| Menéndez-Villanueva, R | 1 |
| Ballesta, A | 1 |
| Touza, R | 1 |
| Perpiñá-Tordera, M | 1 |
| Lecumberri, R | 2 |
| Rosario, E | 1 |
| Pacho, J | 1 |
| Constans, M | 1 |
| Santamaria, A | 1 |
| Mateo, J | 1 |
| Pujol, N | 1 |
| Souto, JC | 1 |
| Fontcuberta, J | 2 |
| Balibrea, JL | 1 |
| Altimiras, J | 1 |
| Larruzea, I | 1 |
| Kakkar, VV | 4 |
| Howes, J | 1 |
| Sharma, V | 1 |
| Kadziola, Z | 1 |
| Oldham, M | 1 |
| Palkimas, S | 1 |
| Hedrick, A | 1 |
| Farkouh, ME | 2 |
| Stone, GW | 2 |
| Lala, A | 2 |
| Bagiella, E | 1 |
| Moreno, PR | 2 |
| Nadkarni, GN | 2 |
| Ben-Yehuda, O | 1 |
| Granada, JF | 1 |
| Dressler, O | 2 |
| Tinuoye, EO | 1 |
| Granada, C | 2 |
| Bustamante, J | 2 |
| Peyra, C | 2 |
| Godoy, LC | 2 |
| Palacios, IF | 2 |
| Fuster, V | 2 |
| Kumar, D | 1 |
| Kaimaparambil, V | 1 |
| Chandralekha, S | 1 |
| Lalchandani, J | 1 |
| Tinuoye, E | 1 |
| Goodman, SG | 1 |
| Esper, RB | 1 |
| Abizaid, A | 1 |
| Varade, D | 1 |
| Betancur, JF | 1 |
| Ricalde, A | 1 |
| Payro, G | 1 |
| Castellano, JM | 1 |
| Hung, IFN | 1 |
| Giustino, G | 1 |
| Feinman, J | 1 |
| Camaj, A | 1 |
| Bienstock, SW | 1 |
| Furtado, RHM | 1 |
| Contreras, J | 1 |
| Owen, R | 1 |
| Bhatt, DL | 1 |
| Pocock, SJ | 1 |
| Jarab, AS | 1 |
| Al-Azzam, S | 1 |
| Badaineh, R | 1 |
| Mukattash, TL | 1 |
| Bsoul, R | 1 |
| Adedeji, A | 1 |
| Chukwura, O | 1 |
| Obafemi, T | 1 |
| McNulty, SB | 1 |
| Reinert, JP | 1 |
| Vera, A | 1 |
| Rivero, F | 1 |
| Salamanca, J | 1 |
| Alvarado-Casas, T | 1 |
| Alfonso, F | 1 |
| Bahabri, A | 1 |
| Chan, AKC | 1 |
| Belostosky, V | 1 |
| Bhatt, MD | 1 |
| Rentsch, CT | 1 |
| Beckman, JA | 1 |
| Tomlinson, L | 1 |
| Gellad, WF | 1 |
| Alcorn, C | 1 |
| Kidwai-Khan, F | 1 |
| Skanderson, M | 1 |
| Brittain, E | 1 |
| King, JT | 1 |
| Ho, YL | 1 |
| Eden, S | 1 |
| Kundu, S | 1 |
| Lann, MF | 1 |
| Greevy, RA | 1 |
| Ho, PM | 1 |
| Heidenreich, PA | 1 |
| Jacobson, DA | 1 |
| Douglas, IJ | 1 |
| Tate, JP | 1 |
| Evans, SJW | 1 |
| Atkins, D | 1 |
| Justice, AC | 1 |
| Freiberg, MS | 1 |
| Mennuni, MG | 1 |
| Renda, G | 1 |
| Grisafi, L | 1 |
| Rognoni, A | 1 |
| Colombo, C | 1 |
| Lio, V | 1 |
| Foglietta, M | 1 |
| Petrilli, I | 1 |
| Pirisi, M | 1 |
| Spinoni, E | 1 |
| Azzolina, D | 1 |
| Hayden, E | 1 |
| Aimaretti, G | 1 |
| Avanzi, GC | 1 |
| Bellan, M | 1 |
| Cantaluppi, V | 1 |
| Capponi, A | 1 |
| Castello, LM | 1 |
| D'Ardes, D | 1 |
| Corte, FD | 1 |
| Gallina, S | 1 |
| Krengli, M | 1 |
| Malerba, M | 1 |
| Pierdomenico, SD | 1 |
| Savoia, P | 1 |
| Zeppegno, P | 1 |
| Sainaghi, PP | 1 |
| Cipollone, F | 1 |
| Patti, G | 1 |
| Goldin, M | 1 |
| Giannis, D | 1 |
| Diab, W | 1 |
| Wang, J | 1 |
| Khanijo, S | 1 |
| Sharifova, G | 1 |
| Cohen, M | 1 |
| Lund, JM | 1 |
| Mignatti, A | 1 |
| Gianos, E | 1 |
| Tafur, A | 1 |
| Lewis, PA | 1 |
| Cohoon, K | 1 |
| Kittelson, JM | 1 |
| Lesser, ML | 1 |
| Sison, CP | 1 |
| Rahman, H | 1 |
| Ochani, K | 1 |
| Hiatt, WR | 1 |
| Dale, RA | 1 |
| Anderson, VE | 1 |
| Bonaca, M | 1 |
| Halperin, JL | 1 |
| Weitz, JI | 1 |
| Spyropoulos, AC | 1 |
| Patel, M | 1 |
| Ahuja, T | 1 |
| Arnouk, S | 1 |
| Gidea, C | 1 |
| Reyentovich, A | 1 |
| Smith, DE | 1 |
| Moazami, N | 1 |
| Papadopoulos, J | 1 |
| Lewis, TC | 1 |
| Whiting, DR | 1 |
| Wall, V | 1 |
| Fleming, KI | 1 |
| Tonna, JE | 1 |
| Nunez, J | 1 |
| Lonardo, N | 1 |
| Shipley, RW | 1 |
| Nirula, R | 1 |
| Pannucci, CJ | 1 |
| Di Minno, G | 1 |
| Polo Friz, H | 1 |
| Scaglione, F | 1 |
| Boracchi, P | 1 |
| Marano, G | 1 |
| Harenberg, J | 3 |
| Swanson, E | 1 |
| Jones, CW | 1 |
| Spasojevic, S | 1 |
| Goh, G | 1 |
| Joseph, Z | 1 |
| Wood, DJ | 1 |
| Yates, PJ | 1 |
| Moffett, BS | 1 |
| Lee-Kim, Y | 1 |
| Galati, M | 1 |
| Mahoney, D | 1 |
| Shah, MD | 1 |
| Teruya, J | 1 |
| Yee, D | 1 |
| Hingorani, SR | 1 |
| Zheng, L | 1 |
| Bullock, AJ | 1 |
| Seery, TE | 1 |
| Harris, WP | 1 |
| Sigal, DS | 1 |
| Braiteh, F | 1 |
| Ritch, PS | 1 |
| Zalupski, MM | 1 |
| Bahary, N | 1 |
| Oberstein, PE | 1 |
| Wang-Gillam, A | 1 |
| Wu, W | 1 |
| Chondros, D | 1 |
| Jiang, P | 1 |
| Khelifa, S | 1 |
| Pu, J | 1 |
| Aldrich, C | 1 |
| Hendifar, AE | 1 |
| Indirayani, I | 1 |
| Kalok, A | 1 |
| Nik Ismail, NA | 1 |
| Shah, SA | 1 |
| Lim, PS | 1 |
| Mohamed Ismail, NA | 1 |
| Nur Azurah, AG | 1 |
| Omar, MH | 1 |
| Shafiee, MN | 1 |
| Vianello, A | 1 |
| Vencato, E | 1 |
| Cantini, M | 1 |
| Zanconato, G | 1 |
| Manfrin, E | 1 |
| Zamo, A | 1 |
| Zorzi, F | 1 |
| Mazzi, F | 1 |
| Martinelli, N | 1 |
| Cavaliere, E | 1 |
| Monari, F | 1 |
| Venturelli, D | 1 |
| Ferrara, F | 1 |
| Olivieri, O | 1 |
| De Franceschi, L | 1 |
| Eubanks, AA | 1 |
| Deering, SH | 1 |
| Thiel, LM | 1 |
| Guimicheva, B | 1 |
| Patel, JP | 1 |
| Roberts, LN | 1 |
| Subramanian, D | 1 |
| Arya, R | 1 |
| Amos, LE | 1 |
| Silvey, M | 1 |
| Hall, M | 1 |
| Witmer, CM | 1 |
| Carpenter, SL | 1 |
| Schaal, JV | 1 |
| Benhamou, D | 1 |
| Boyer, K | 1 |
| Mercier, FJ | 1 |
| Kim, GH | 2 |
| Park, BY | 1 |
| Bae, TY | 1 |
| Kang, JW | 1 |
| In, Y | 1 |
| Klein, HH | 1 |
| Miyares, MA | 1 |
| DeCarolis, DD | 2 |
| Johnson, GJ | 3 |
| Cohen, AT | 13 |
| Boyd, RA | 1 |
| Mandema, JW | 1 |
| Dicarlo, L | 1 |
| Pak, R | 1 |
| Demirtas, A | 1 |
| Azboy, I | 1 |
| Bulut, M | 1 |
| Ucar, BY | 1 |
| Alabalik, U | 1 |
| Necmioglu, NS | 1 |
| Bertoletti, L | 1 |
| Lega, JC | 1 |
| Accassat, S | 1 |
| Merah, A | 1 |
| Décousus, H | 4 |
| Farooqui, A | 1 |
| Hiser, B | 1 |
| Barnes, SL | 1 |
| Litofsky, NS | 1 |
| Pelzer, U | 1 |
| Hilbig, A | 1 |
| Stieler, JM | 1 |
| Bahra, M | 1 |
| Sinn, M | 1 |
| Gebauer, B | 1 |
| Dörken, B | 1 |
| Riess, H | 4 |
| Fuji, T | 2 |
| Fujita, S | 2 |
| Kawai, Y | 2 |
| Nakamura, M | 2 |
| Kimura, T | 2 |
| Kiuchi, Y | 1 |
| Abe, K | 2 |
| Tachibana, S | 2 |
| Burtness, B | 1 |
| Powell, M | 1 |
| Catalano, P | 1 |
| Berlin, J | 1 |
| Liles, DK | 1 |
| Chapman, AE | 1 |
| Mitchell, E | 1 |
| Benson, AB | 1 |
| Figueiró-Filho, EA | 1 |
| Aydos, RD | 1 |
| Senefonte, FR | 1 |
| Ferreira, CM | 1 |
| Pereira, EF | 1 |
| Oliveira, VM | 1 |
| Menezes, GP | 1 |
| Bósio, MA | 1 |
| Ozdemir, D | 1 |
| Tam, AA | 1 |
| Dirikoc, A | 1 |
| Ersoy, R | 1 |
| Cakir, B | 1 |
| Saheb Sharif-Askari, F | 1 |
| Syed Sulaiman, SA | 1 |
| Saheb Sharif-Askari, N | 1 |
| Al Sayed Hussain, A | 1 |
| Railey, MJ | 1 |
| Wang, CJ | 1 |
| Ibusuki, K | 1 |
| Ushida, H | 1 |
| Revigliono, JI | 1 |
| Cornavaca, T | 1 |
| Becerra, F | 1 |
| Albertini, R | 1 |
| Contreras, AE | 1 |
| Tabares, A | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Gionis, MN | 1 |
| Ioannou, CV | 1 |
| Kontopodis, N | 1 |
| Balalis, K | 1 |
| Elalamy, I | 2 |
| Gerotziafas, GT | 3 |
| Borden, M | 1 |
| Kiernan, MS | 1 |
| Pham, DT | 1 |
| DeNofrio, D | 1 |
| Sylvia, L | 1 |
| Kathmann, W | 1 |
| Ong, WL | 1 |
| Koh, TL | 1 |
| Fletcher, J | 1 |
| Gruen, R | 1 |
| Royce, P | 1 |
| Demirelli, Y | 1 |
| Tekgündüz, KŞ | 1 |
| Caner, İ | 1 |
| Kara, M | 1 |
| Stephenson, ML | 1 |
| Serra, AE | 1 |
| Neeper, JM | 1 |
| Caballero, DC | 1 |
| McNulty, J | 1 |
| Sharfman, ZT | 1 |
| Campbell, JC | 1 |
| Mirocha, JM | 1 |
| Spitzer, AI | 1 |
| Andújar Mateos, A | 1 |
| Matoses Chirivella, C | 1 |
| Rodríguez Lucena, FJ | 1 |
| Navarro Ruiz, A | 1 |
| Goette, A | 1 |
| Merino, JL | 1 |
| Ezekowitz, MD | 2 |
| Zamoryakhin, D | 1 |
| Melino, M | 1 |
| Jin, J | 1 |
| Mercuri, MF | 1 |
| Grosso, MA | 1 |
| Fernandez, V | 1 |
| Al-Saady, N | 1 |
| Pelekh, N | 1 |
| Merkely, B | 1 |
| Zenin, S | 1 |
| Kushnir, M | 1 |
| Spinar, J | 1 |
| Batushkin, V | 1 |
| de Groot, JR | 1 |
| Lip, GY | 1 |
| Raheemullah, A | 1 |
| Laurence, TN | 1 |
| Vilanova, E | 1 |
| Glauser, BF | 1 |
| Oliveira, SM | 1 |
| Tovar, AM | 1 |
| Mourão, PA | 1 |
| Cavusoglu, T | 1 |
| Kismet, K | 1 |
| Ozcan, N | 1 |
| Kucuk, B | 1 |
| Barlas, AM | 1 |
| Bozkirli, BO | 1 |
| Celepli, P | 1 |
| Senes, M | 1 |
| Bolat, S | 1 |
| Hucumenoglu, S | 1 |
| Ahmed, AK | 1 |
| Youssef, A | 1 |
| Skeik, N | 1 |
| Diab, YA | 1 |
| Ramakrishnan, K | 1 |
| Ferrell, B | 1 |
| Chounoune, R | 1 |
| Alfares, FA | 1 |
| Endicott, KM | 1 |
| Rooney, S | 1 |
| Corcoran, J | 1 |
| Zurakowski, D | 1 |
| Berger, JT | 1 |
| Shankar, V | 1 |
| Nath, DS | 1 |
| Hering, D | 1 |
| Piper, C | 1 |
| Horstkotte, D | 1 |
| Steger, V | 1 |
| Bail, DH | 1 |
| Graf, D | 1 |
| Walker, T | 1 |
| Rittig, K | 1 |
| Ziemer, G | 1 |
| Hatef, DA | 1 |
| Kenkel, JM | 1 |
| Nguyen, MQ | 1 |
| Farkas, JP | 1 |
| Abtahi, F | 1 |
| Rohrich, RJ | 1 |
| Brown, SA | 1 |
| González-Fajardo, JA | 1 |
| Martin-Pedrosa, M | 1 |
| Castrodeza, J | 1 |
| Tamames, S | 1 |
| Vaquero-Puerta, C | 1 |
| Hussain, A | 1 |
| Mahmood, H | 1 |
| Barry, M | 1 |
| Hahn, DK | 1 |
| Kellner, CP | 1 |
| Komotar, RJ | 2 |
| Starke, R | 1 |
| Garrett, MC | 1 |
| Yao, J | 1 |
| Cleveland, J | 1 |
| Mayer, SA | 1 |
| Connolly, ES | 3 |
| Starke, RM | 1 |
| Turpie, AG | 25 |
| Bauer, KA | 7 |
| Davidson, BL | 4 |
| Fisher, WD | 2 |
| Gent, M | 10 |
| Huo, MH | 1 |
| Sinha, U | 1 |
| Gretler, DD | 1 |
| Rosencher, N | 4 |
| Arnaout, L | 1 |
| Chabbouh, T | 1 |
| Bellamy, L | 1 |
| Albaladejo, P | 1 |
| Hammerstingl, C | 5 |
| Omran, H | 5 |
| Tripp, C | 2 |
| Poetzsch, B | 1 |
| Henes, J | 1 |
| Oberländer, Y | 1 |
| Tepe, G | 1 |
| Schneider, W | 1 |
| Balletshofer, B | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Chin, PL | 1 |
| Amin, MS | 1 |
| Yang, KY | 1 |
| Yeo, SJ | 1 |
| Lo, NN | 1 |
| Bhatia, V | 1 |
| Arora, P | 1 |
| Parida, AK | 1 |
| Mittal, A | 1 |
| Pandey, AK | 1 |
| Kaul, U | 1 |
| Neviaser, AS | 1 |
| Chang, C | 1 |
| Lyman, S | 1 |
| Della Valle, AG | 1 |
| Haas, SB | 2 |
| McLintock, C | 2 |
| McCowan, LM | 1 |
| North, RA | 2 |
| Longo, UG | 1 |
| Maffulli, N | 1 |
| Denaro, V | 1 |
| Bui, HT | 1 |
| Krisnaswami, A | 1 |
| Le, CU | 1 |
| Chan, J | 1 |
| Shenoy, BN | 1 |
| Barras, MA | 2 |
| Duffull, SB | 3 |
| Atherton, JJ | 2 |
| Green, B | 3 |
| Bustelos, R | 1 |
| Ayala, R | 1 |
| Martinez, J | 1 |
| Martin, MA | 1 |
| Toledo, T | 1 |
| Grande, S | 1 |
| Garfia, C | 1 |
| Moreno, A | 1 |
| Perez, B | 1 |
| Meneu, JC | 1 |
| Moreno, E | 1 |
| Ribera, C | 1 |
| Knesek, MJ | 1 |
| Litinas, E | 1 |
| Adiguzel, C | 1 |
| Hopkinson, W | 1 |
| Hoppensteadt, D | 2 |
| Lassen, M | 1 |
| Fareed, J | 3 |
| Panni, JK | 1 |
| Panni, MK | 1 |
| Attaran, S | 1 |
| Somov, P | 1 |
| Awad, WI | 1 |
| Ahmed, I | 1 |
| Gertner, E | 1 |
| Nelson, WB | 1 |
| House, CM | 1 |
| Dahiya, R | 1 |
| Anderson, CP | 1 |
| Benditt, DG | 1 |
| Zhu, DW | 1 |
| Mitchell, L | 2 |
| Lambers, M | 1 |
| Flege, S | 1 |
| Kenet, G | 1 |
| Li-Thiao-Te, V | 1 |
| Holzhauer, S | 1 |
| Bidlingmaier, C | 1 |
| Frühwald, MC | 1 |
| Heller, C | 1 |
| Schmidt, W | 1 |
| Pautard, B | 1 |
| Nowak-Göttl, U | 2 |
| Ignjatovic, V | 2 |
| Najid, S | 1 |
| Newall, F | 1 |
| Summerhayes, R | 1 |
| Monagle, P | 3 |
| Axon, RN | 1 |
| Cawley, PJ | 1 |
| Saeed, CR | 1 |
| Jacobson, BF | 1 |
| Pravin, M | 1 |
| Aziz, RH | 1 |
| Serasheini, M | 1 |
| Dominique, TG | 1 |
| Omel'ianovskiĭ, VV | 1 |
| Zagorodniĭ, NV | 1 |
| Margieva, AV | 1 |
| Tsfasman, FM | 1 |
| Trame, MN | 1 |
| Krümpel, A | 1 |
| Male, C | 1 |
| Hempel, G | 1 |
| Klamroth, R | 1 |
| Gottstein, S | 1 |
| Essers, E | 1 |
| Landgraf, H | 2 |
| Leithäuser, B | 1 |
| Kasch, F | 1 |
| Broemel, T | 1 |
| Park, JW | 1 |
| Bottaro, FJ | 1 |
| Ceresetto, JM | 1 |
| Palumbo, A | 2 |
| Cavo, M | 1 |
| Bringhen, S | 1 |
| Zamagni, E | 1 |
| Romano, A | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Galli, M | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Baldini, L | 1 |
| Elice, F | 1 |
| Callea, V | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Tosi, P | 1 |
| Boccadoro, M | 2 |
| Mohammed, R | 1 |
| Pynsent, PB | 1 |
| Shapiro, M | 1 |
| Wistinghausen, B | 1 |
| Midulla, P | 1 |
| Chin, C | 1 |
| Saliba, W | 1 |
| Nitzan, O | 1 |
| Rock, W | 1 |
| Ron, G | 1 |
| Zalman, L | 1 |
| Goldstein, L | 1 |
| Lavi, I | 1 |
| Elias, M | 1 |
| DeDea, L | 1 |
| Mertyn, E | 1 |
| Einecke, D | 1 |
| Macafee, B | 1 |
| Campbell, JP | 1 |
| Ashpole, K | 1 |
| Cox, M | 1 |
| Matthey, F | 1 |
| Acton, L | 1 |
| Yentis, SM | 1 |
| Billè, A | 1 |
| Okiror, L | 1 |
| Karenovics, W | 1 |
| Pilling, J | 1 |
| Lang-Lazdunski, L | 1 |
| Amin, AG | 1 |
| Ng, J | 1 |
| Hsu, W | 1 |
| Pradilla, G | 1 |
| Raza, S | 1 |
| Quinones-Hinojosa, A | 1 |
| Lim, M | 1 |
| Biteker, M | 1 |
| Tekkeşin, Aİ | 1 |
| Can, MM | 1 |
| Dayan, A | 1 |
| Ilhan, E | 1 |
| Türkmen, FM | 1 |
| Byrne, MT | 1 |
| Bergman, AK | 1 |
| Ruiz, AI | 1 |
| Silver, BJ | 1 |
| Maciejewski, JP | 1 |
| Tiu, RV | 1 |
| Thorson, JG | 1 |
| Clairmont, MA | 1 |
| Leuthner, AM | 1 |
| Rector, TS | 1 |
| Minichiello, T | 1 |
| Zwicker, JI | 1 |
| Liebman, HA | 1 |
| Caughey, T | 1 |
| Campigotto, F | 1 |
| Rosovsky, R | 1 |
| Mantha, S | 1 |
| Kessler, CM | 2 |
| Eneman, J | 1 |
| Raghavan, V | 1 |
| Lenz, HJ | 1 |
| Bullock, A | 1 |
| Buchbinder, E | 1 |
| Neuberg, D | 1 |
| Furie, B | 1 |
| Reich-Schupke, S | 1 |
| Doerler, M | 1 |
| Altmeyer, P | 1 |
| Stücker, M | 1 |
| Eriksson, BI | 12 |
| Lassen, MR | 7 |
| Nerurkar, J | 1 |
| Wade, WE | 2 |
| Martin, BC | 1 |
| Borja, J | 1 |
| Olivella, P | 1 |
| Curto, J | 1 |
| Morris, E | 1 |
| Thaler, H | 1 |
| Sim, E | 1 |
| Goldhaber, SZ | 4 |
| Dunn, K | 1 |
| Gerhard-Herman, M | 1 |
| Park, JK | 1 |
| Black, PM | 1 |
| de Lissovoy, G | 1 |
| Subedi, P | 1 |
| Alikhan, R | 4 |
| Andereya, S | 1 |
| Kälicke, T | 1 |
| Hopf, KF | 1 |
| Buschmeier, M | 1 |
| Muhr, G | 1 |
| Ginsberg, JS | 5 |
| Chan, WS | 1 |
| Bates, SM | 3 |
| Kaatz, S | 1 |
| White, RH | 1 |
| Kleber, FX | 1 |
| Witt, C | 1 |
| Vogel, G | 1 |
| Koppenhagen, K | 3 |
| Schomaker, U | 1 |
| Flosbach, CW | 1 |
| Ferreira, I | 1 |
| Dos, L | 1 |
| Tornos, P | 2 |
| Nicolau, I | 2 |
| Permanyer-Miralda, G | 2 |
| Soler-Soler, J | 2 |
| Frederiksen, SG | 1 |
| Hedenbro, JL | 1 |
| Norgren, L | 1 |
| Priglinger, U | 1 |
| Delle Karth, G | 1 |
| Geppert, A | 1 |
| Joukhadar, C | 1 |
| Graf, S | 1 |
| Berger, R | 1 |
| Hülsmann, M | 1 |
| Spitzauer, S | 1 |
| Pabinger, I | 1 |
| Heinz, G | 1 |
| Freedman, MD | 1 |
| Alexander, R | 1 |
| Hampton, KK | 1 |
| Piecuch, W | 1 |
| Sokołowska, B | 1 |
| Dmoszyńska, A | 1 |
| Furmanik, F | 1 |
| Carroll, DN | 1 |
| Hudson, EB | 1 |
| Streif, W | 1 |
| Goebel, G | 1 |
| Chan, AK | 2 |
| Massicotte, MP | 2 |
| Combe, S | 3 |
| Samama, MM | 10 |
| Desjardins, L | 6 |
| Eldor, A | 5 |
| Janbon, C | 4 |
| Leizorovicz, A | 7 |
| Olsson, CG | 7 |
| Colwell, CW | 4 |
| Berkowitz, SD | 2 |
| Lotke, PA | 2 |
| Lieberman, JR | 1 |
| Neubauer, J | 1 |
| McElhattan, JL | 1 |
| Peters, GR | 1 |
| Francis, CW | 1 |
| Gordois, A | 1 |
| Posnett, J | 1 |
| Borris, L | 2 |
| Bossuyt, P | 1 |
| Jönsson, B | 1 |
| Levy, E | 1 |
| de Pouvourville, G | 1 |
| Hardy, JF | 1 |
| Dahl, OE | 6 |
| Mouret, P | 1 |
| Kälebo, P | 6 |
| Panfilov, S | 1 |
| Eskilson, C | 1 |
| Andersson, M | 1 |
| Freij, A | 1 |
| Rowan, JA | 1 |
| Taylor, RS | 1 |
| Warner, GT | 1 |
| Perry, CM | 2 |
| Stellbrink, C | 4 |
| Nixdorff, U | 4 |
| Hofmann, T | 3 |
| Lehmacher, W | 3 |
| Daniel, WG | 3 |
| Hanrath, P | 3 |
| Geller, C | 2 |
| Mügge, A | 3 |
| Sehnert, W | 2 |
| Schmidt-Lucke, C | 4 |
| Schmidt-Lucke, JA | 3 |
| Czerny, M | 1 |
| Fleck, T | 1 |
| Salat, A | 1 |
| Zimpfer, D | 1 |
| Klepetko, W | 1 |
| Wolner, E | 1 |
| Mueller, MR | 1 |
| Evans, HC | 1 |
| Bara, L | 1 |
| Boutitie, F | 1 |
| Bechtold, H | 2 |
| Janssen, D | 2 |
| Reeves, P | 1 |
| Cooke, J | 1 |
| Lloyd, A | 1 |
| Hutchings, A | 1 |
| Wolak, A | 1 |
| Ayzenberg, Y | 1 |
| Cafri, C | 1 |
| Gilutz, H | 1 |
| Ilia, R | 1 |
| Zahger, D | 1 |
| Lobo, BL | 1 |
| Abdel-Razeq, H | 1 |
| Michaels, LA | 1 |
| Gurian, M | 1 |
| Hegyi, T | 1 |
| Drachtman, RA | 1 |
| Spruill, WJ | 1 |
| Leslie, RB | 1 |
| Offord, R | 1 |
| Lloyd, AC | 1 |
| Anderson, P | 1 |
| Bearne, A | 1 |
| Dranitsaris, G | 2 |
| Kahn, SR | 4 |
| Stumpo, C | 1 |
| Paton, TW | 1 |
| Martineau, J | 1 |
| Smith, R | 1 |
| Knovich, MA | 1 |
| Lesser, GJ | 1 |
| Brotman, DJ | 2 |
| Jaffer, AK | 2 |
| Hurbanek, JG | 1 |
| Morra, N | 1 |
| Lawrence, YR | 1 |
| Chakroun, T | 1 |
| Hettiarachchi, R | 2 |
| Bravo, ML | 1 |
| Ahnfelt, L | 1 |
| Stangier, J | 1 |
| Reilly, P | 1 |
| Bjorvatn, A | 1 |
| Kristiansen, F | 1 |
| Pulido, P | 1 |
| Hardwick, ME | 2 |
| Morris, BA | 1 |
| Enyart, JJ | 1 |
| Jones, RJ | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Kiktev, VG | 1 |
| Batyraliev, TA | 1 |
| Pershukov, IV | 1 |
| Ahmed, M | 1 |
| Bragg, L | 1 |
| Seshadri, N | 1 |
| Qadeer, MA | 1 |
| Klein, A | 1 |
| Farkas, E | 1 |
| Péley, G | 1 |
| Mátrai, Z | 1 |
| Rényi-Vámos, F | 1 |
| Köves, I | 1 |
| Spinler, SA | 1 |
| Friedman, RJ | 3 |
| Quenet, S | 1 |
| Levine, M | 2 |
| Merli, G | 2 |
| Derobert, E | 1 |
| Kwong, LM | 1 |
| Irwin, MW | 1 |
| Misselwitz, F | 4 |
| Ferguson, RE | 1 |
| Critchfield, A | 1 |
| Leclaire, A | 1 |
| Ajkay, N | 1 |
| Vasconez, HC | 1 |
| Goodin, S | 1 |
| Schiff, RL | 1 |
| Shrier, I | 1 |
| Strulovitch, C | 1 |
| Hammouda, W | 1 |
| Cohen, E | 1 |
| Zukor, D | 1 |
| Toll, A | 1 |
| Gallardo, F | 1 |
| Abella, ME | 1 |
| Barranco, C | 1 |
| Pujol, RM | 1 |
| Ol'binskaia, LI | 1 |
| Kolosova, KIu | 1 |
| Nesterova, SG | 1 |
| Egorova, TD | 1 |
| Fedorova, AIu | 1 |
| Haas, S | 5 |
| Huisman, MV | 1 |
| Kakkar, AK | 3 |
| Verheugt, FW | 1 |
| Lederle, FA | 1 |
| Sacks, JM | 1 |
| Fiore, L | 1 |
| Landefeld, CS | 1 |
| Steinberg, N | 1 |
| Peters, RW | 1 |
| Eid, AA | 1 |
| Sebastian, J | 1 |
| Stasek, JE | 1 |
| Fye, CL | 1 |
| Paar, WD | 2 |
| Meurer, J | 1 |
| Grewe, R | 1 |
| Klein, HU | 1 |
| De Carolis, S | 1 |
| Ferrazzani, S | 1 |
| De Stefano, V | 1 |
| Garofalo, S | 1 |
| Fatigante, G | 1 |
| Rossi, E | 1 |
| Leone, G | 1 |
| Caruso, A | 1 |
| Bischoff, A | 1 |
| Ageno, W | 1 |
| Rodríguez, A | 1 |
| Vallano, A | 1 |
| Schädlich, PK | 2 |
| Kentsch, M | 1 |
| Weber, M | 1 |
| Kämmerer, W | 1 |
| Brecht, JG | 2 |
| Nadipelli, V | 2 |
| Huppertz, E | 2 |
| Hull, RD | 3 |
| Schellong, SM | 4 |
| Tapson, VF | 1 |
| Monreal, M | 3 |
| Wildgoose, P | 1 |
| Yusen, RD | 1 |
| Sukhoversha, OA | 1 |
| Feng, Y | 1 |
| Kane-Gill, SL | 1 |
| Bobek, MB | 1 |
| Bies, RR | 1 |
| Nadir, Y | 1 |
| Mazor, Y | 1 |
| Reuven, B | 1 |
| Sarig, G | 1 |
| Brenner, B | 2 |
| Krivoy, N | 1 |
| Rus, C | 1 |
| Zeldis, JB | 1 |
| Rodeghiero, F | 1 |
| Westrich, GH | 1 |
| Bottner, F | 1 |
| Windsor, RE | 1 |
| Laskin, RS | 1 |
| Sculco, TP | 1 |
| Deitcher, SR | 1 |
| Rigas, JR | 1 |
| Lyons, RM | 1 |
| Lee, RH | 1 |
| Goodwin, TM | 1 |
| Buckenmaier, CC | 1 |
| Shields, CH | 1 |
| Auton, AA | 1 |
| Evans, SL | 1 |
| Croll, SM | 1 |
| Bleckner, LL | 1 |
| Brown, DS | 1 |
| Stojadinovic, A | 1 |
| Wiernikowski, JT | 1 |
| Chan, A | 2 |
| Lo, G | 1 |
| Carroll, RC | 1 |
| Craft, RM | 1 |
| Whitaker, GL | 1 |
| Snider, CC | 1 |
| Kirby, RK | 1 |
| Elder, RF | 1 |
| Hennessey, MD | 1 |
| Myers, J | 1 |
| Gouin-Thibault, I | 1 |
| Drouet, L | 2 |
| Simoneau, G | 1 |
| Di Castillo, H | 1 |
| Siguret, V | 1 |
| Pautas, E | 1 |
| O'Donnell, MJ | 1 |
| Johnson, J | 1 |
| Robinson, M | 1 |
| Zondag, M | 1 |
| Turpie, I | 1 |
| Aghassarian, M | 1 |
| Bal Dit-Sollier, C | 1 |
| Lacut, K | 1 |
| Heilmann, JJ | 1 |
| Mottier, D | 2 |
| Burnett, RS | 1 |
| Clohisy, JC | 1 |
| Wright, RW | 1 |
| McDonald, DJ | 1 |
| Shively, RA | 1 |
| Givens, SA | 1 |
| Barrack, RL | 1 |
| Gallus, A | 1 |
| Raskob, GE | 1 |
| Segers, AE | 1 |
| Lensing, AW | 2 |
| Quinlan, DJ | 1 |
| Eikelboom, JW | 1 |
| Sidhu, PS | 1 |
| Rivas-Gándara, N | 1 |
| Ferreira-González, I | 1 |
| Torrents, A | 1 |
| Arellano-Rodrigo, E | 1 |
| Vallejo, N | 1 |
| Igual, A | 1 |
| Berges, A | 1 |
| Epinat, M | 1 |
| Zufferey, P | 1 |
| Alamartine, E | 1 |
| Tranchand, B | 1 |
| Schmidt, H | 1 |
| von der Recke, G | 1 |
| O'Brien, SH | 1 |
| Lee, H | 1 |
| Ritchey, AK | 1 |
| Laux, V | 1 |
| Perzborn, E | 1 |
| Kubitza, D | 1 |
| Kurth, AA | 1 |
| van Dijk, CN | 1 |
| Frostick, SP | 2 |
| Hantel, S | 1 |
| Schnee, J | 1 |
| Tebbe, U | 4 |
| Kothari, SN | 1 |
| Lambert, PJ | 1 |
| Mathiason, MA | 1 |
| Dorr, LD | 1 |
| Gendelman, V | 1 |
| Maheshwari, AV | 1 |
| Boutary, M | 1 |
| Wan, Z | 1 |
| Long, WT | 1 |
| Drossbach, M | 1 |
| Sorino, M | 2 |
| Colonna, P | 1 |
| De Luca, L | 2 |
| Carerj, S | 1 |
| Oliva, E | 1 |
| De Tommasi, SM | 1 |
| Conti, U | 1 |
| Iacopi, F | 1 |
| D'Agostino, C | 1 |
| D'Amato, N | 1 |
| Pettinati, G | 1 |
| Montericcio, V | 1 |
| Cualbu, A | 1 |
| De Luca, I | 2 |
| Assadian, A | 1 |
| Knöbl, P | 1 |
| Hübl, W | 1 |
| Senekowitsch, C | 1 |
| Klingler, A | 1 |
| Pfaffelmeyer, N | 1 |
| Hagmüller, GW | 1 |
| Hardy, RG | 1 |
| Williams, L | 1 |
| Dixon, JM | 1 |
| Borris, LC | 2 |
| Babiak, I | 1 |
| Jabłoński, T | 1 |
| Serafin, J | 1 |
| Peters, DH | 1 |
| Goa, KL | 2 |
| Saltiel, E | 1 |
| Saya, F | 1 |
| Levin, PE | 1 |
| Faunø, P | 1 |
| Suomalainen, O | 1 |
| Rehnberg, V | 1 |
| Hansen, TB | 1 |
| Krøner, K | 1 |
| Soimakallio, S | 1 |
| Nielsen, E | 1 |
| Fejgin, MD | 1 |
| Lourwood, DL | 1 |
| Carter, CA | 1 |
| Skoutakis, VA | 1 |
| Spiro, TE | 3 |
| West, ME | 1 |
| Tooms, RE | 1 |
| Joe, RH | 1 |
| Knutson, TJ | 1 |
| Kandrotas, RJ | 1 |
| Nelson-Piercy, C | 2 |
| Sturridge, F | 1 |
| de Swiet, M | 2 |
| Letsky, E | 1 |
| Wiig, JN | 1 |
| Solhaug, JH | 2 |
| Bilberg, T | 1 |
| Bjerkeset, T | 1 |
| Edwin, B | 1 |
| Grüner, OP | 1 |
| Havig, O | 1 |
| Holter, O | 1 |
| Knudsen, G | 1 |
| Lundblad, R | 1 |
| Macklon, NS | 1 |
| Greer, IA | 2 |
| Reid, AW | 1 |
| Walker, ID | 2 |
| Leclerc, J | 1 |
| Anderson, D | 1 |
| Weitz, J | 2 |
| Ginsberg, J | 1 |
| Demers, C | 2 |
| Kovacs, M | 1 |
| Dulitzki, M | 1 |
| Pauzner, R | 1 |
| Langevitz, P | 1 |
| Pras, M | 1 |
| Many, A | 1 |
| Schiff, E | 1 |
| Leclerc, JR | 2 |
| Geerts, WH | 4 |
| Laflamme, GH | 1 |
| L'Espérance, B | 1 |
| Kassis, J | 1 |
| Cruickshank, M | 1 |
| Whitman, L | 1 |
| Delorme, F | 1 |
| Gibaldi, M | 1 |
| Wittkowsky, AK | 1 |
| Force, RW | 1 |
| Benoni, G | 2 |
| Björgell, O | 2 |
| Fredin, H | 2 |
| Hedlundh, U | 1 |
| Nicolas, S | 2 |
| Nilsson, P | 1 |
| Nylander, G | 2 |
| Anderson, DR | 4 |
| Gross, M | 1 |
| Robinson, KS | 1 |
| Wells, PS | 5 |
| Pedell, L | 1 |
| Vochelle, N | 1 |
| Nilsson, PE | 2 |
| Hedlund, U | 1 |
| Letsky, EA | 1 |
| Grosset, AB | 1 |
| Beynon, J | 1 |
| Rodgers, GM | 1 |
| Walsh-McMonagle, D | 1 |
| Green, D | 1 |
| Hunt, D | 1 |
| Buoncristiani, P | 1 |
| Severi, P | 1 |
| Pini, M | 1 |
| D'Angelo, A | 1 |
| Beltrametti, C | 1 |
| Damiani, M | 1 |
| Andrioli, GC | 1 |
| Pugliese, R | 1 |
| Iorio, A | 1 |
| Brambilla, G | 1 |
| Reiertsen, O | 1 |
| Larsen, S | 1 |
| Mocco, J | 1 |
| Dunn, CJ | 4 |
| Etchells, E | 1 |
| McLeod, RS | 2 |
| Geerts, W | 2 |
| Barton, P | 2 |
| Detsky, AS | 1 |
| Ziaja, K | 1 |
| Simka, M | 1 |
| Krupowies, A | 1 |
| Dugaj, M | 1 |
| Ludyga, T | 1 |
| Collis, DK | 1 |
| Paulson, R | 1 |
| McCutchen, JW | 1 |
| Bigler, GT | 1 |
| Lutz, S | 1 |
| Spandorfer, JM | 1 |
| Lynch, S | 1 |
| Weitz, HH | 1 |
| Fertel, S | 1 |
| Merli, GJ | 1 |
| Darmon, JY | 2 |
| Nguyen, H | 1 |
| Weisslinger, N | 1 |
| Bonnar, J | 1 |
| Norris, LA | 1 |
| Greene, R | 1 |
| Tseng, CW | 1 |
| Huntington, J | 1 |
| Hynson, JM | 1 |
| Sosis, MB | 1 |
| Calderon, EJ | 1 |
| Varela, JM | 1 |
| Gonzalez de la Puente, MA | 1 |
| Dunsworth, GA | 1 |
| Hilpert, U | 1 |
| Gürlich, R | 1 |
| Salaj, P | 1 |
| Hrachovinová, I | 1 |
| Dix, D | 1 |
| Andrew, M | 2 |
| Marzinotto, V | 3 |
| Charpentier, K | 1 |
| Bridge, S | 1 |
| deVeber, G | 1 |
| Leaker, M | 1 |
| Finsen, V | 2 |
| Prifti, E | 1 |
| Bonacchi, M | 1 |
| Leacche, M | 1 |
| Miraldi, F | 1 |
| Stiefelhagen, P | 1 |
| Panizo, C | 1 |
| Ellison, J | 1 |
| Morris, TA | 1 |
| Marsh, JJ | 1 |
| Konopka, R | 1 |
| Pedersen, CA | 1 |
| Chiles, PG | 1 |
| Sniderman, KW | 1 |
| Greenwood, C | 1 |
| Gregoire, RC | 1 |
| Taylor, BM | 1 |
| Silverman, RE | 1 |
| Atkinson, KG | 1 |
| Burnstein, M | 1 |
| Marshall, JC | 2 |
| Burul, CJ | 1 |
| Ross, T | 1 |
| Wilson, SR | 1 |
| Hoek, JA | 1 |
| Comp, PC | 1 |
| Whitsett, TL | 1 |
| Gardiner, GA | 1 |
| Landon, GC | 1 |
| Jové, M | 1 |
| Zaw, HM | 1 |
| Stetsenko, AP | 1 |
| Smorzhevskiĭ, VI | 1 |
| Komarov, AI | 1 |
| Panchenko, EP | 1 |
| Elhasid, R | 1 |
| Lanir, N | 1 |
| Sharon, R | 1 |
| Weyl Ben Arush, M | 1 |
| Levin, C | 1 |
| Postovsky, S | 1 |
| Ben Barak, A | 1 |
| Lepercq, J | 1 |
| Conard, J | 2 |
| Borel-Derlon, A | 1 |
| Boudignat, O | 1 |
| Francoual, C | 1 |
| Priollet, P | 1 |
| Cohen, C | 1 |
| Yvelin, N | 1 |
| Schved, JF | 1 |
| Tournaire, M | 1 |
| Borg, JY | 1 |
| Del Salvatore, B | 1 |
| Diuguid, DL | 1 |
| Perry, DJ | 1 |
| Nuijten, MJ | 1 |
| Berto, P | 1 |
| Kosa, J | 1 |
| Spreafico, A | 1 |
| Murashige, N | 1 |
| Kami, M | 1 |
| Priestley, M | 1 |
| Scacewater, R | 1 |
| Le Moigne-Amrani, A | 1 |
| Dietrich-Neto, F | 1 |
| Doggrell, SA | 2 |
| Mason, JA | 1 |
| Norwood, SH | 1 |
| McAuley, CE | 1 |
| Berne, JD | 1 |
| Vallina, VL | 1 |
| Kerns, DB | 1 |
| Grahm, TW | 1 |
| Short, K | 1 |
| McLarty, JW | 1 |
| Massicotte, P | 2 |
| Shields, K | 1 |
| Szechtman, B | 1 |
| Gore, M | 1 |
| Kelkar, P | 1 |
| Rege, N | 1 |
| Ross, C | 1 |
| Jeske, W | 1 |
| Eschenfelder, V | 1 |
| Iqbal, O | 1 |
| Ahsan, A | 1 |
| Boeckl, O | 1 |
| Boneu, B | 1 |
| Bordenave, L | 1 |
| Brehm, OA | 1 |
| Brücke, P | 1 |
| Coccheri, S | 1 |
| Galland, F | 1 |
| Jarrige, J | 1 |
| LeQuerrec, A | 1 |
| Parraguette, E | 1 |
| Roder, JD | 1 |
| Roos, M | 1 |
| Rüschemeyer, C | 1 |
| Siewert, JR | 1 |
| Vinazzer, H | 1 |
| Wenzel, E | 1 |
| Gehling, H | 1 |
| Giannadakis, K | 1 |
| Lefering, R | 1 |
| Hessmann, M | 1 |
| Achenbach, S | 1 |
| Gotzen, L | 1 |
| Breddin, HK | 1 |
| Hach-Wunderle, V | 1 |
| Nakov, R | 1 |
| Wirth, T | 1 |
| Schneider, B | 1 |
| Lomb, M | 1 |
| Tüylü, H | 1 |
| Egbring, R | 1 |
| Griss, P | 1 |
| Wellington, K | 1 |
| McClellan, K | 1 |
| Jarvis, B | 2 |
| Stricker, H | 1 |
| Mombelli, G | 1 |
| Pechlaner, C | 1 |
| Gritsch, W | 1 |
| Gerlach, HE | 3 |
| Abletshauser, C | 3 |
| Sieder, C | 3 |
| Rossol, S | 1 |
| Pfeiffer, B | 1 |
| Melzer, N | 2 |
| Bramlage, P | 2 |
| Bauersachs, R | 2 |
| Kolb, G | 1 |
| Bodamer, I | 1 |
| Galster, H | 1 |
| Seidlmayer, C | 1 |
| Grambach, K | 1 |
| Koudela, K | 1 |
| Eisele, RR | 1 |
| Becker, C | 1 |
| Paal, V | 1 |
| Spannagel, U | 1 |
| Brom, J | 2 |
| Weidinger, G | 2 |
| Kleindienst, A | 1 |
| Harvey, HB | 1 |
| Mater, E | 1 |
| Bronst, J | 1 |
| Flack, J | 1 |
| Herenz, K | 1 |
| Haupt, WF | 1 |
| Schön, R | 1 |
| Diener, HC | 1 |
| Ringelstein, EB | 1 |
| von Kummer, R | 1 |
| Rektor, I | 1 |
| Csányi, A | 1 |
| Schneider, D | 1 |
| Klingelhöfer, J | 1 |
| Desborough, MJR | 1 |
| Doyle, AJ | 1 |
| Griffiths, A | 1 |
| Retter, A | 1 |
| Breen, KA | 1 |
| Hunt, BJ | 1 |
| Kovacs, MJ | 6 |
| Lazo-Langner, A | 2 |
| Blostein, M | 1 |
| Schulman, S | 1 |
| Sabri, E | 1 |
| Solymoss, S | 2 |
| Ramsay, T | 2 |
| Yeo, E | 1 |
| Rodger, MA | 2 |
| Madahar, P | 1 |
| Gonzalez, CM | 1 |
| Luzi, M | 1 |
| Capucci, A | 1 |
| Di Pasquale, G | 1 |
| Zagnoni, S | 1 |
| McKellar, SH | 1 |
| Thompson, JL | 2 |
| Garcia-Rinaldi, RF | 1 |
| Macdonald, RJ | 1 |
| Sundt, TM | 2 |
| Schaff, HV | 2 |
| Schmid, P | 1 |
| Brodmann, D | 1 |
| Fischer, AG | 1 |
| Wuillemin, WA | 1 |
| Cook, D | 2 |
| Sinuff, T | 1 |
| Zytaruk, N | 2 |
| Rabbat, C | 1 |
| Lee, A | 1 |
| O'Donnell, M | 1 |
| Thabane, L | 1 |
| Linkins, L | 1 |
| Treleaven, D | 1 |
| Patel, R | 1 |
| Meade, M | 2 |
| Crowther, M | 3 |
| Douketis, J | 2 |
| Tischenko, A | 1 |
| Gula, LJ | 1 |
| Yee, R | 1 |
| Klein, GJ | 1 |
| Skanes, AC | 1 |
| Krahn, AD | 1 |
| Wiwanitkit, V | 1 |
| Gredilla, E | 1 |
| Pérez-Ferrer, A | 1 |
| Canser, E | 1 |
| Alonso, E | 1 |
| Martínez Serrano, B | 1 |
| Gilsanz, F | 1 |
| Hasan, K | 1 |
| Acedillo, R | 1 |
| Zeller, M | 1 |
| Hackam, DG | 1 |
| Bucci, C | 1 |
| Sinclair, A | 1 |
| Fremes, SE | 1 |
| Guyatt, G | 1 |
| Walter, S | 1 |
| Heels-Ansdell, D | 1 |
| Warkentin, TE | 1 |
| Cooper, DJ | 1 |
| Vallance, S | 1 |
| Qushmaq, I | 1 |
| Rocha, M | 1 |
| Berwanger, O | 1 |
| Vlahakis, NE | 1 |
| Matziolis, D | 1 |
| Matziolis, G | 1 |
| Perka, C | 1 |
| MacKinnon, M | 1 |
| Westphal, M | 1 |
| McCormick, B | 1 |
| Knoll, G | 1 |
| Gillette, BP | 1 |
| DeSimone, LJ | 1 |
| Trousdale, RT | 1 |
| Pagnano, MW | 1 |
| Sierra, RJ | 1 |
| Ebina, Y | 1 |
| Yamada, H | 1 |
| Kato, EH | 1 |
| Yamamoto, R | 1 |
| Sakuragi, N | 1 |
| Fujimoto, S | 1 |
| Lindbratt, S | 1 |
| Bylock, A | 2 |
| Frison, L | 2 |
| Eriksson, UG | 2 |
| Welin, L | 1 |
| Gustafsson, D | 2 |
| Komorny, KM | 1 |
| Ewald, JR | 1 |
| Jacobsen, AF | 1 |
| Qvigstad, E | 1 |
| Sandset, PM | 1 |
| Vanscoy, GJ | 1 |
| Lee, AY | 3 |
| Levine, MN | 4 |
| Baker, RI | 3 |
| Bowden, C | 2 |
| Prins, M | 2 |
| Rickles, FR | 2 |
| Haley, S | 1 |
| Gunzenhauser, D | 1 |
| Sawitzki, H | 1 |
| Fung, S | 1 |
| Blot, E | 1 |
| Gutman, F | 1 |
| Thannberger, A | 1 |
| Pineo, GF | 2 |
| Vaitkus, PT | 3 |
| Zacharski, L | 1 |
| Jiménez, JA | 1 |
| Roncales, J | 1 |
| Vilaseca, B | 1 |
| Rodger, M | 1 |
| Pokrovskaia, EV | 1 |
| Handschin, AE | 1 |
| Trentz, OA | 1 |
| Hoerstrup, SP | 1 |
| Kock, HJ | 1 |
| Wanner, GA | 1 |
| Trentz, O | 1 |
| Averkov, OV | 1 |
| Al-Yaseen, E | 1 |
| Anderson, J | 1 |
| Martin, J | 1 |
| Kucher, N | 1 |
| Keeney, M | 1 |
| Mackinnon, KM | 1 |
| Hirota, Y | 1 |
| Sakai, M | 1 |
| Nakabayashi, M | 1 |
| Heerey, A | 1 |
| Suri, S | 1 |
| O'Neill, JL | 1 |
| Flanagan, PS | 1 |
| Zaleon, CR | 1 |
| Copeland, LA | 1 |
| Karthaus, M | 1 |
| Kretzschmar, A | 1 |
| Kröning, H | 1 |
| Biakhov, M | 1 |
| Irwin, D | 1 |
| Marschner, N | 1 |
| Slabber, C | 1 |
| Fountzilas, G | 1 |
| Garin, A | 1 |
| Abecasis, NG | 1 |
| Baronius, W | 1 |
| Steger, GG | 1 |
| Südhoff, T | 1 |
| Giorgetti, C | 1 |
| Reichardt, P | 1 |
| Burton, A | 1 |
| Bick, RL | 1 |
| Malý, J | 1 |
| Dulícek, P | 1 |
| Penka, M | 1 |
| Malý, R | 1 |
| Gumulec, J | 1 |
| Tincani, E | 1 |
| Mannucci, C | 1 |
| Casolari, B | 1 |
| Turrini, F | 1 |
| Crowther, MA | 1 |
| Prisco, D | 1 |
| Cenci, AM | 1 |
| Bondi, M | 1 |
| Vincent, M | 1 |
| Rasmussen, MS | 2 |
| Jorgensen, LN | 2 |
| Wille-Jørgensen, P | 2 |
| Nielsen, JD | 1 |
| Horn, A | 1 |
| Mohn, AC | 1 |
| Sømod, L | 1 |
| Olsen, B | 1 |
| Cothren, CC | 1 |
| Smith, WR | 1 |
| Moore, EE | 1 |
| Morgan, SJ | 1 |
| Hamner, CE | 1 |
| Potter, DD | 1 |
| Lewin, M | 1 |
| Robins, HI | 1 |
| O'Neill, A | 1 |
| Gilbert, M | 1 |
| Olsen, M | 1 |
| Sapiente, R | 1 |
| Berkey, B | 1 |
| Mehta, M | 1 |
| Herzog, S | 1 |
| Rath, W | 1 |
| Kuhn, W | 1 |
| Lafoz, E | 1 |
| Olive, A | 1 |
| del Rio, L | 1 |
| Vedia, C | 1 |
| Luomanmäki, K | 1 |
| Grankvist, S | 1 |
| Hallert, C | 1 |
| Jauro, I | 1 |
| Ketola, K | 1 |
| Kim, HC | 1 |
| Kiviniemi, H | 1 |
| Koskivirta, H | 1 |
| Sörskog, L | 1 |
| Vilkko, P | 1 |
| Gilmore, G | 1 |
| Thom, J | 1 |
| Sorkin, EM | 1 |
| Flordal, PA | 1 |
| Berggvist, D | 1 |
| Burmark, US | 1 |
| Ljungström, KG | 1 |
| Törngren, S | 1 |
| Ward, B | 1 |
| Pradhan, S | 1 |
| Blombäck, M | 2 |
| Bremme, K | 2 |
| Hellgren, M | 1 |
| Siegbahn, A | 1 |
| Lindberg, H | 1 |
| Bauld, DL | 1 |
| Morau, D | 1 |
| Barthelet, Y | 1 |
| Spilmann, E | 1 |
| d'Athis, F | 1 |
| Rey, E | 1 |
| Rivard, GE | 1 |
| van Rooijen, M | 1 |
| Yu, A | 1 |
| Schambeck, CM | 1 |
| Eberl, E | 1 |
| Geisen, U | 1 |
| Grossmann, R | 1 |
| Keller, F | 1 |
| Khinev, S | 1 |
| Tsoneva, D | 1 |
| Darfinova, K | 1 |
| Kamenova, B | 1 |
| Yar'mov, N | 1 |
| Häfeli, R | 1 |
| Kraljevic, S | 1 |
| Wehrli, C | 1 |
| Goede, J | 1 |
| Conen, D | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Kaaja, R | 1 |
| Arfwidsson, AC | 1 |
| Fager, G | 1 |
| Schinzel, H | 1 |
| Bahlmann, F | 1 |
| Peetz, D | 1 |
| Savvidis, S | 1 |
| Himmrich, L | 1 |
| Klotz, M | 1 |
| O'Flynn, AM | 1 |
| Watts, M | 1 |
| Wall, D | 1 |
| Molefe, C | 1 |
| O'Keeffe, D | 1 |
| Finucane, P | 1 |
| Koczorek, M | 1 |
| Jensen, CD | 1 |
| Steval, A | 1 |
| Partington, PF | 1 |
| Reed, MR | 1 |
| Muller, SD | 1 |
| Fassiadis, N | 1 |
| Stavrianakis, C | 1 |
| Moghraby, OS | 1 |
| Gandhi, P | 1 |
| Smedley, FH | 1 |
| Cheer, SM | 1 |
| Foster, R | 1 |
| Kuhle, S | 1 |
| Dinyari, M | 1 |
| Vegh, P | 1 |
| Mitchell, D | 1 |
| Pieniaszek, H | 1 |
| Mitchell, LG | 1 |
| Cook, G | 1 |
| Depares, J | 1 |
| Singh, M | 1 |
| McElduff, P | 1 |
| Friedel, HA | 1 |
| Balfour, JA | 1 |
| Sors, H | 1 |
| Charbonnier, B | 1 |
| Page, Y | 1 |
| Laaban, JP | 2 |
| Azarian, R | 1 |
| Laurent, M | 1 |
| Hirsch, JL | 1 |
| Ferrari, E | 1 |
| Bosson, JL | 1 |
| Beau, B | 1 |
| Lausen, I | 1 |
| Jensen, R | 1 |
| Lyng, KM | 1 |
| Andersen, M | 1 |
| Raaschou, HO | 1 |
| Achkar, A | 1 |
| Horellou, MH | 1 |
| Rose, P | 1 |
| Bell, D | 1 |
| Green, ES | 1 |
| Davenport, A | 1 |
| Fegan, C | 1 |
| Grech, H | 1 |
| O'Shaughnessy, D | 1 |
| Voke, J | 1 |
| Hainer, JW | 1 |
| Barrett, JS | 1 |
| Assaid, CA | 1 |
| Fossler, MJ | 1 |
| Cox, DS | 1 |
| Leathers, T | 1 |
| Leese, PT | 1 |
| Powers, P | 1 |
| Neemeh, J | 1 |
| Willan, A | 1 |
| Skingley, P | 1 |
| Heit, JA | 2 |
| Bona, R | 1 |
| Cabanas, V | 1 |
| Corson, JD | 1 |
| Elliott, CG | 2 |
| Lyons, R | 1 |
| Trowbridge, AA | 1 |
| Morrey, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.[NCT00951574] | Phase 3 | 1,166 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)[NCT00203580] | Phase 4 | 910 participants | Interventional | 1994-12-31 | Completed | ||
| LITE Study, Appendix A (HOME-LITE), Amendment 6[NCT00203658] | Phase 4 | 400 participants | Interventional | 1997-04-30 | Completed | ||
| Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism[NCT02355548] | 200 participants (Anticipated) | Observational | 2012-12-31 | Completed | |||
| Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients[NCT02795065] | 100 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| FREEDOM COVID Anticoagulation Strategy Randomized Trial[NCT04512079] | Phase 4 | 3,460 participants (Actual) | Interventional | 2020-09-08 | Completed | ||
| A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer[NCT01839487] | Phase 2 | 279 participants (Actual) | Interventional | 2013-05-14 | Completed | ||
| Pilot Study of Intensified Chemotherapy and Simultaneous Treatment With Heparin in Out-patients With Pancreatic Cancer.[NCT01945879] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)[NCT01181141] | Phase 3 | 92 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)[NCT01181102] | Phase 3 | 716 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily[NCT02070237] | Phase 1 | 90 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial F[NCT02072434] | Phase 3 | 2,199 participants (Actual) | Interventional | 2014-03-25 | Completed | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles[NCT00908960] | Phase 2 | 70 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794] | Phase 3 | 25 participants (Actual) | Interventional | 2017-10-25 | Terminated (stopped due to Interim Analysis showed no significance) | ||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818] | Phase 3 | 3,494 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958] | 150 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707] | Phase 4 | 1,200 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | ||
| Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses[NCT01828697] | Phase 4 | 1,110 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.[NCT02597218] | 350 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| The Use of Low Molecular Weight Heparin in Traumatic Brain Injury[NCT00170378] | Phase 4 | 300 participants | Interventional | 2002-12-31 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412] | Phase 3 | 3,254 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function[NCT00264693] | 96 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism[NCT02898051] | 370 participants (Actual) | Observational | 2011-08-31 | Active, not recruiting | |||
| Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855] | 240 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism[NCT01164046] | Phase 3 | 56 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Due to slow inclusion of patients) | ||
| Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients[NCT01602432] | 0 participants (Actual) | Observational | 2012-11-30 | Withdrawn (stopped due to Project did not meet criteria of a research study and was confirmed as a Quality Initiative Project) | |||
| A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00028678] | Phase 2 | 45 participants (Actual) | Interventional | 2002-07-11 | Completed | ||
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ORR was defined as percentage of participants who achieved either a complete response (CR) or partial response (PR) regardless of confirmation, as assessed by RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions; Any pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT01839487)
Timeframe: From the date of randomization until last date on study treatment (maximum exposure: 30.72 months for PAG, and 20.27 months for AG)
| Intervention | percentage of participants (Number) |
|---|---|
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 40.4 |
| AG: Nab-paclitaxel + Gemcitabine | 32.7 |
Overall survival was defined as the time from randomization until death from any cause. Participants who died or were lost to follow-up by the date of analysis data cutoff were censored at their last contact date. (NCT01839487)
Timeframe: From randomization until death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG)
| Intervention | months (Median) |
|---|---|
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 9.59 |
| AG: Nab-paclitaxel + Gemcitabine | 9.23 |
TE events were identified by applying the Medical Dictionary for Regulatory Activities (MedDRA) Standardized MedDRA Queries (SMQ) search strategy for 3 SMQs: TE arterial, TE venous, and TE vessel type unspecified and mixed arterial and venous. TE events were considered by the Sponsor to be adverse events (AEs) of special interest. All TE events, regardless of type of event, severity, or seriousness were reported. Participants with multiple events were counted only once. A summary of serious and all other non-serious adverse events regardless of causality is located in the 'Reported AE section'. (NCT01839487)
Timeframe: From first exposure to any study drug (PEGPH20, NAB, GEM) through 30 days after end of treatment visit (maximum exposure: 30.72 months for PAG)
| Intervention | percentage of participants (Number) |
|---|---|
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 14.0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. (NCT01839487)
Timeframe: From first exposure to any study drug (PEGPH20, NAB, GEM) through 30 days after end of treatment visit (maximum exposure: 30.72 months for PAG and 20.27 months for AG)
| Intervention | percentage of participants (Number) |
|---|---|
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 99.4 |
| AG: Nab-paclitaxel + Gemcitabine | 98.0 |
PFS: time from randomization until first occurrence of disease progression, either by central radiologic determination (Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) or by clinical progression determined by Investigator, or death during treatment period from any cause. Radiological disease progression was defined as at least a 20 percent (%) increase in sum of diameters of target lesions, taking as reference the smallest sum on study thus far, nadir (this included baseline sum if that was the smallest on study); Sum must also demonstrate an absolute increase of at least 5 millimeters (mm); Appearance of one or more new lesions; Unequivocal progression of existing non-target lesions. Surviving participants without disease progression were censored for PFS analysis at the date of last evaluable post-baseline tumor assessment. Surviving participants without any post-baseline disease assessment were censored on Day 1. PFS was estimated using Kaplan-Meier (KM) method. (NCT01839487)
Timeframe: From the date of randomization until disease progression or death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG)
| Intervention | months (Median) |
|---|---|
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 6.05 |
| AG: Nab-paclitaxel + Gemcitabine | 5.26 |
Samples were analyzed for PEGPH20 concentration using a validated electrochemiluminescence immunoassay. Plasma samples to assess the potential effects of NAB+GEM on PEGH20 PK were collected in the PAG treatment group in the run-in phases (Run-in Phase 1: Original PEGPH20 formulation [3.5 mg/mL], and Run-in Phase 2: New PEGPH20 formulation [0.3 mg/mL]). (NCT01839487)
Timeframe: Pre-PEGPH20 dosing and 15 minutes, 1 hour, 2 hours, and 4 hours post-PEGPH20 dosing on Days 1 and 15 of Cycle 1
| Intervention | hours*ng/mL (Mean) | |
|---|---|---|
| Day 1 | Day 15 | |
| Run-in Phase 1-PAG: PEGPH20 (Original Formulation) + NAB + GEM | 1837.93575 | 2807.94210 |
| Run-in Phase 2- PAG: PEGPH20 (New Formulation) + NAB + GEM | 2143.30319 | 2423.01690 |
Samples were analyzed for PEGPH20 concentration using a validated electrochemiluminescence immunoassay. Plasma samples to assess the potential effects of NAB+GEM on PEGH20 pharmacokinetic (PK) were collected in the PAG treatment group in the run-in phases (Run-in Phase 1: Original PEGPH20 formulation [3.5 mg/mL], and Run-in Phase 2: New PEGPH20 formulation [0.3 mg/mL]). (NCT01839487)
Timeframe: Pre-PEGPH20 dosing and 15 minutes, 1 hour, 2 hours, and 4 hours post-PEGPH20 dosing on Days 1 and 15 of Cycle 1
| Intervention | nanograms/milliliter (ng/mL) (Mean) | |
|---|---|---|
| Day 1 | Day 15 | |
| Run-in Phase 1-PAG: PEGPH20 (Original Formulation) + NAB + GEM | 72.1 | 82.9 |
| Run-in Phase 2- PAG: PEGPH20 (New Formulation) + NAB + GEM | 67.8 | 84.1 |
PFS was defined as time from randomization until first occurrence of disease progression, either by central radiologic determination (RECIST version 1.1) or by clinical progression determined by Investigator, or death during treatment period from any cause. Disease progression was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study thus far, nadir (this included baseline sum if that was the smallest on study); Sum must also demonstrate an absolute increase of at least 5 mm; Appearance of one or more new lesions; Unequivocal progression of existing non-target lesions. Surviving participants without disease progression were censored for PFS analysis at the date of last evaluable post-baseline tumor assessment. Surviving participants without any post-baseline disease assessment were censored on Day 1. PFS was estimated using KM method. PFS was measured in HA-high and HA-low participants. (NCT01839487)
Timeframe: From the date of randomization until disease progression or death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG)
| Intervention | months (Median) | |
|---|---|---|
| HA-High | HA-Low | |
| AG: Nab-paclitaxel + Gemcitabine | 5.19 | 5.26 |
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 9.23 | 5.59 |
Samples were analyzed for PEGPH20 concentration using a validated electrochemiluminescence immunoassay. Plasma samples to assess the potential effects of NAB+GEM on PEGH20 PK were collected in the PAG treatment group in the run-in phases (Run-in Phase 1: Original PEGPH20 formulation [3.5 mg/mL], and Run-in Phase 2: New PEGPH20 formulation [0.3 mg/mL]). (NCT01839487)
Timeframe: Pre-PEGPH20 dosing and 15 minutes, 1 hour, 2 hours, and 4 hours post-PEGPH20 dosing on Days 1 and 15 of Cycle 1
| Intervention | hours (Median) | |
|---|---|---|
| Day 1 | Day 15 | |
| Run-in Phase 1-PAG: PEGPH20 (Original Formulation) + NAB + GEM | 0.430 | 0.790 |
| Run-in Phase 2- PAG: PEGPH20 (New Formulation) + NAB + GEM | 0.865 | 0.810 |
Bleeding events during the period from the start of treatment with the study drug (study treatment) to the day of the follow-up examination were assessed as the primary endpoints. (NCT01181141)
Timeframe: 2 weeks
| Intervention | percentage of subjects with bleeds (Number) |
|---|---|
| DU-176b | 3.4 |
| Enoxaparin Sodium | 6.9 |
(NCT01181102)
Timeframe: 2 weeks
| Intervention | percentage of subjects with bleeds (Number) |
|---|---|
| DU-176b | 6.2 |
| Enoxaparin Sodium | 3.7 |
"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity Deep Vein Thrombosis (DVT) confirmed by unilateral venography at the end of study treatment~Definite diagnosis of symptomatic Pulmonary Embolism (PE)~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of venous Thromboembolism (VTE)" (NCT01181102)
Timeframe: 2 weeks
| Intervention | percent of participants with VTE events (Number) |
|---|---|
| DU-176b | 7.4 |
| Enoxaparin Sodium | 13.9 |
Our primary outcome will be to assess the Anti Xa level drawn 3.5-4 hours after the third dose of Lovenox (enoxaparin) to assess if this is in the prophylactic range. (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | IU/mL (Mean) |
|---|---|
| Enoxaparin Once Daily | 0.14 |
| Enoxaparin Twice Daily | 0.30 |
We will assess if any of the subjects has an Anti Xa level that is in the supraprophylactic range (treatment range). (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | participants (Number) |
|---|---|
| Enoxaparin Once Daily | 0 |
| Enoxaparin Twice Daily | 0 |
(NCT02072434)
Timeframe: Randomization to end of follow-up (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 0.5 |
| Warfarin | 1 |
(NCT02072434)
Timeframe: During treatment period (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 1.5 |
| Warfarin | 1 |
(NCT02072434)
Timeframe: From randomization to the end of follow-up (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 0.7 |
| Warfarin | 1.4 |
2-month cumulative incidence of venous thromboembolism (VTE) is the probability of experiencing within 2 months of study entry the following events: any symptomatic proximal or distal lower extremity deep vein thrombosis, symptomatic pulmonary embolism or fatal pulmonary embolism diagnosed by autopsy, or asymptomatic proximal deep vein thrombosis diagnosed by screening compression ultrasound. (NCT00908960)
Timeframe: Assessment with lower extremity ultrasound occured at day 60/ month 2
| Intervention | percent probability (Number) |
|---|---|
| High TFMP: Enoxaparin | 5.6 |
| High TFMP: Observation | 27.2 |
| Low TFMP: Observation | 7.2 |
Incidence is the number of patients experiencing at least one major hemorrhage events as defined according to International Society on Thrombosis and Haemostasis (ISTH) guidelines. (Schulman and Kearon 2005) (NCT00908960)
Timeframe: Assessed during the 60 day therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| High TFMP: Enoxaparin | 0 |
| High TFMP: Observation | 0 |
| Low TFMP: Observation | 0 |
Overall survival is defined as the time from study entry to death or date last known alive and estimated using Kaplan-Meier (KM) methods. (NCT00908960)
Timeframe: Assessed up to approximately 30 months
| Intervention | months (Median) |
|---|---|
| High TFMP: Enoxaparin | 17.8 |
| High TFMP: Observation | 11.8 |
| Low TFMP: Observation | 17.3 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 23 |
| Bupivicaine + Exparel | 23 |
Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery
| Intervention | milligram (Mean) |
|---|---|
| Bupivicaine | 90 |
| Bupivicaine + Exparel | 76 |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 4 |
| Bupivicaine + Exparel | 4 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
All cause death, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 3 |
| Dabigatran 150mg | 3 |
| Enoxaparin | 0 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 28 |
| Dabigatran 150mg | 38 |
| Enoxaparin | 36 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 23 |
| Dabigatran 150mg | 35 |
| Enoxaparin | 33 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 5 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 3 |
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 6 |
| Dabigatran 150mg | 9 |
| Enoxaparin | 1 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 46 |
| Dabigatran 150mg | 72 |
| Enoxaparin | 57 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 53 |
| Dabigatran 150mg | 75 |
| Enoxaparin | 60 |
Volume of blood loss for treated and operated patients during surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 457 |
| Dabigatran 150mg | 435 |
| Enoxaparin | 463 |
Blood transfusion for treated and operated patients on Day of surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Patients with >=1 transfusions | Patients with >=1 non-autologous transfusions | |
| Dabigatran 150mg | 531 | 266 |
| Dabigatran 220mg | 517 | 259 |
| Enoxaparin | 542 | 286 |
Frequency of patients with possible clinically significant abnormalities. (NCT00168818)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(1103;1097;1103) | AST decrease N=(1103;1097;1103) | ALT increase N=(1103;1098;1103) | ALT decrease N=(1103;1098;1103) | Bilirubin increase N=(1102;1094;1102) | Bilirubin decrease N=(1102;1094;1102) | |
| Dabigatran 150mg | 16 | 0 | 29 | 0 | 24 | 0 |
| Dabigatran 220mg | 11 | 0 | 28 | 0 | 25 | 0 |
| Enoxaparin | 29 | 0 | 59 | 0 | 34 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major | Clinical relevant | Minor | None | |
| Dabigatran 150mg | 15 | 55 | 72 | 1021 |
| Dabigatran 220mg | 23 | 48 | 70 | 1005 |
| Enoxaparin | 18 | 40 | 74 | 1022 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168818)
Timeframe: end of treatment to day 91±7
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptotic Deep Vein Thrombosis | symptotic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 150mg | 4 | 1 | 1 | 0 | 2 |
| Dabigatran 220mg | 1 | 0 | 1 | 0 | 0 |
| Enoxaparin | 5 | 3 | 0 | 1 | 1 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
70 reviews available for dalteparin and Thromboembolism
| Article | Year |
|---|---|
Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.
Topics: Adult; Age Factors; Anticoagulants; Body Mass Index; Dermatitis, Allergic Contact; Drug Administrati | 2017 |
Low-molecular-weight heparin for the prevention of postoperative venous thromboembolism after abdominal surgery: a review.
Topics: Anticoagulants; Colonic Diseases; Digestive System Diseases; Digestive System Neoplasms; Digestive S | 2005 |
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; He | 1996 |
[The use of the new anticoagulant Fraxiparin in preventing and treating thromboembolism].
Topics: Anticoagulants; Contraindications; Humans; Nadroparin; Thromboembolism | 1995 |
Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Topics: Absorption; Aging; Anticoagulants; Chemical Fractionation; Cost-Benefit Analysis; Dose-Response Rela | 1997 |
[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)].
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Internal Medicine; Nadropari | 1998 |
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hep | 2001 |
Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
Topics: Absorption; Animals; Biological Availability; Blood Coagulation; Half-Life; Heparin; Heparin, Low-Mo | 1994 |
Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Postoperative | 2003 |
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
Topics: Anticoagulants; COVID-19; Critical Care; Enoxaparin; Hospitalization; Humans; Pyrazoles; Pyridones; | 2022 |
Anticoagulation Strategies in the Management of Lemierre Syndrome: A Systematic Review of the Literature.
Topics: Anticoagulants; Atrial Fibrillation; Disease Management; Drug Administration Schedule; Enoxaparin; H | 2021 |
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Drug-Related Side Effects | 2017 |
Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Humans; Postpartum Period; Practice Guidelines as Topic | 2019 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
Update on Brazilian biosimilar enoxaparins.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Brazil; Cost-Benefit Analysis; Enoxaparin; Humans; Throm | 2016 |
[Rivaroxaban (Xarelto): efficacy and safety].
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2008 |
The coagulation system in children: developmental and pathophysiological considerations.
Topics: Adult; Aging; Anticoagulants; Antithrombin III; Blood Coagulation; Child; Child Development; Enoxapa | 2011 |
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Topics: Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Factor Xa Inhibitors; Fond | 2002 |
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Enoxaparin; Health Ca | 2002 |
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Confidence In | 2002 |
Venous thromboembolism in cancer patients: expanding horizons.
Topics: Antineoplastic Agents; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
Low-molecular-weight heparins: are they all the same?
Topics: Angina, Unstable; Blood Coagulation Tests; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Heparin, Lo | 2003 |
A bioavailability study in the proposed patient population--with much more needed now.
Topics: Anticoagulants; Antithrombin III; Biological Availability; Critical Care; Critical Illness; Drug Mon | 2003 |
Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III | 2003 |
Enoxaparin: in the prevention of venous thromboembolism in medical patients.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Humans; Thromboembolism | 2001 |
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; | 2004 |
The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fondaparinux; Humans; Orthopedic Procedu | 2004 |
Anticoagulation with low-molecular-weight heparin in patients with heart diseases.
Topics: Anticoagulants; Atrial Fibrillation; Dalteparin; Enoxaparin; Heart Diseases; Heparin, Low-Molecular- | 2004 |
Prophylaxis of venous thromboembolism in medical patients.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hum | 2004 |
Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Humans; Meta-Analysis as Topic; Orthopedic Procedures; Pol | 2004 |
Pentasaccharides. The new anticoagulants.
Topics: Anticoagulants; Enoxaparin; Female; Fondaparinux; Humans; Male; Orthopedic Procedures; Polysaccharid | 2004 |
Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefi | 2004 |
The management of thromboembolic disease in patients with central nervous system malignancies.
Topics: Anticoagulants; Central Nervous System Neoplasms; Dalteparin; Diet; Enoxaparin; Heparin; Humans; Lif | 2004 |
Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic | 2004 |
[Stroke and other thromboembolic complications of atrial fibrillation. Part VII. Prevention of cardioversion related thromboembolism].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Echocardiography, Transesophageal; El | 2005 |
Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmona | 2005 |
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
Topics: Anticoagulants; Azetidines; Benzylamines; Dalteparin; Double-Blind Method; Enoxaparin; Fibrinolytic | 2005 |
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Topics: Aged; Anticoagulants; Dalteparin; Enoxaparin; Fondaparinux; Humans; Middle Aged; Polysaccharides; Pu | 2005 |
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Bleeding Time; Clinical Trials, Phase II as Topic; Di | 2007 |
[Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Echocardiography, Transesophageal; Electr | 2007 |
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl | 1994 |
Clinical profile of enoxaparin in a high-risk situation.
Topics: Clinical Trials as Topic; Dextrans; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1994 |
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.
Topics: Biological Availability; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; He | 1995 |
Low molecular weight heparins and their use in obstetrics and gynecology.
Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular- | 1994 |
Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complicat | 1993 |
Contemporary use of and future roles for heparin in antithrombotic therapy.
Topics: Anticoagulants; Antithrombins; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; | 1995 |
Low-molecular-weight heparins in clinical practice.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Dalteparin; Enoxaparin; Fibrinoly | 1998 |
[Treatment of venous thromboembolism].
Topics: Administration, Oral; Adult; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Hepar | 2000 |
Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as | 2000 |
Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial.
Topics: Anticoagulants; Enoxaparin; Humans; Randomized Controlled Trials as Topic; Thromboembolism; Treatmen | 2001 |
Treating venous thromboembolism: enoxaparin.
Topics: Ambulatory Care; Anticoagulants; Contraindications; Cost-Benefit Analysis; Drug Costs; Enoxaparin; H | 2001 |
Cost-effectiveness of enoxaparin as thromboprophylaxis in acutelly ill medical patients from the Italian NHS perspective.
Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Humans; Recurrence; Thromboembolis | 2002 |
Overview of the clinical results of pentasaccharide in major orthopedic surgery.
Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Huma | 2001 |
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Fondaparinux; Humans; P | 2002 |
Review of enoxaparin and its clinical applications in venous and arterial thromboembolism.
Topics: Anticoagulants; Biological Availability; Drug Evaluation; Economics, Pharmaceutical; Enoxaparin; Hal | 2002 |
Optimizing prophylaxis of venous thromboembolism.
Topics: Arthroplasty, Replacement; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enoxaparin; F | 2002 |
Reviparin as prophylaxis for thromboembolism after leg injury and hip replacement.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Heparin, Low-Molecular-Weight; | 2003 |
Reviparin sodium clivarine: a review of its therapeutic use.
Topics: Anticoagulants; Coronary Disease; Coronary Restenosis; Heparin, Low-Molecular-Weight; Humans; Myocar | 2004 |
Efficacy and safety of Clivarin and other LMWHs in general surgery: a meta-analysis.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Hematoma; Heparin, Low-Molecular-Weight; Huma | 1993 |
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Child; Female; Hemorrhage; Heparin, Low-Mole | 2001 |
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage].
Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Hemorrha | 2003 |
The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy.
Topics: Abortion, Habitual; Analgesia, Epidural; Anticoagulants; Bone Density; Dalteparin; Female; Guideline | 2002 |
Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
Topics: Anticoagulants; Blood Coagulation; Coronary Disease; Dalteparin; Heparin, Low-Molecular-Weight; Huma | 2004 |
Cancer-associated thrombosis: focus on extended therapy with dalteparin.
Topics: Anticoagulants; Dalteparin; Evidence-Based Medicine; Humans; Neoplasms; Thromboembolism; Venous Thro | 2006 |
[Prevention of venous thromboembolism in internal medicine and neurology].
Topics: Anticoagulants; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Interna | 2006 |
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Topics: Anticoagulants; Blood Coagulation; Dalteparin; Fibrinolytic Agents; Humans; Thromboembolism | 1996 |
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
Topics: Blood Coagulation; Coronary Disease; Dalteparin; Drug Costs; Drug Interactions; Economics, Pharmaceu | 2000 |
Death after joint replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; | 2000 |
Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Topics: Age Factors; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents | 2004 |
Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
Topics: Animals; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Thrombophlebit | 1994 |
152 trials available for dalteparin and Thromboembolism
| Article | Year |
|---|---|
Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Anticoagulants; Female; Hemostatic Techniques; Hep | 2009 |
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Double-Blind Method; Factor Xa Inhibitors; Female; Fibr | 2009 |
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplat | 2011 |
Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Autopsy; Double-Blind Method; Female; | 2005 |
A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Fibrinolyt | 2006 |
[Two models of thromboprophylaxis in acutely ill medical inpatients].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Feasibility Stud | 2007 |
[Prophylaxis of thromboembolic complications in bariatric surgery].
Topics: Adolescent; Adult; Aged; Anticoagulants; Bariatric Surgery; Humans; Middle Aged; Nadroparin; Obesity | 2007 |
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
Topics: Adolescent; Adult; Blood Coagulation; Cross-Over Studies; Dalteparin; Enoxaparin; Humans; Injections | 1995 |
[Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Heparin; Humans; Injections, Subcutaneous; Male; Nadrop | 1995 |
[Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent].
Topics: Adult; Aged; Ambulatory Care; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; N | 1994 |
[A clinical trial of the preparation Fraxiparin].
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Factor Xa; Female; Hemostasis; Humans; Middle Ag | 1993 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
[Comparison of 2 low molecular weight heparins in patients undergoing major abdominal surgery].
Topics: Abdomen; Adult; Aged; Blood Coagulation Factors; Blood Loss, Surgical; Dalteparin; Female; Fibrinoly | 1996 |
A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Confidence Interv | 1997 |
[Rationalization of risk factors for venous thromboembolism in medical inpatients. A prospective study].
Topics: Adult; Aged; Anticoagulants; France; Heparin, Low-Molecular-Weight; Humans; Incidence; Inpatients; M | 2000 |
[Thromboembolic prophylaxis after major abdominal surgery].
Topics: Abdomen; Bandages; Female; Fibrinolytic Agents; Hematoma; Humans; Injections, Subcutaneous; Male; Mi | 2001 |
Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
Topics: Adult; Anastomosis, Roux-en-Y; Anticoagulants; Body Mass Index; Female; Gastric Bypass; Humans; Inje | 2001 |
[Low molecular weight heparin (parnaparin) versus calcium heparin in the prevention of thromboembolic disease in general surgery].
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; | 1994 |
[Thromboembolic disease: prevention with low-molecular weight heparin in general surgery. Preliminary results].
Topics: Aged; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Surgical Procedures, Operati | 1994 |
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Fibrinolytic Agents; Hemoglobins; Hemorrh | 2003 |
[Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease?].
Topics: Aged; Female; Heparin, Low-Molecular-Weight; Home Nursing; Humans; Male; Prospective Studies; Pulmon | 2006 |
Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study.
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 2006 |
Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Colonoscopy; Female; Follow-Up Studies; Gastroscopy; | 2007 |
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Female | 2000 |
Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Thromboe | 2022 |
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19.
Topics: Anticoagulants; Blood Coagulation; COVID-19; Enoxaparin; Humans; Thromboembolism | 2023 |
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Enoxaparin; | 2021 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2018 |
Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Gynecologic Surgical Procedures; Humans; Middle Age | 2018 |
An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Computer Simu | 2013 |
Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury.
Topics: Adult; Aged; Anticoagulants; Brain Injuries; Chemoprevention; Clinical Protocols; Cohort Studies; En | 2013 |
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2014 |
Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Topics: Aged; Blood Loss, Surgical; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; | 2014 |
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antige | 2016 |
Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Kne | 2014 |
A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Topics: Adult; Blood Coagulation; Body Mass Index; Chemoprevention; Dose-Response Relationship, Drug; Drug A | 2016 |
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Enoxaparin; Factor Xa Inhibitors; | 2016 |
Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.
Topics: Anticoagulants; Coumarins; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Ag | 2008 |
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Topics: Administration, Oral; Adult; Aged; Arthroplasty, Replacement, Knee; Canada; Dose-Response Relationsh | 2009 |
How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Drug Monitoring; Enoxa | 2009 |
Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Asian People; Enoxaparin; Female; Fibrinol | 2009 |
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Humans; Kidney; Ki | 2009 |
Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins.
Topics: Acute Disease; Acute-Phase Proteins; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacem | 2010 |
Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administratio | 2010 |
A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; | 2011 |
Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study.
Topics: Adolescent; Anticoagulants; Body Weight; Child; Child, Preschool; Cohort Studies; Enoxaparin; Factor | 2010 |
Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations.
Topics: Algorithms; Anticoagulants; Drug Monitoring; Enoxaparin; Humans; Kidney Diseases; Models, Statistica | 2010 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Perioperative bridging anticoagulation therapy in at-risk patients undergoing elective arthroplasty surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty; Elective Surgical Procedures; Enoxaparin; Fem | 2010 |
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).
Topics: Aged; Aged, 80 and over; Anticoagulants; Cell-Derived Microparticles; Enoxaparin; Female; Fibrin Fib | 2013 |
Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis.
Topics: Bandages; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Double-Blind Method; Enoxaparin; F | 2002 |
Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
Topics: Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; En | 2002 |
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; H | 2003 |
Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Topics: Aged; Analysis of Variance; Anticoagulants; Antithrombin III; Body Mass Index; Creatinine; Critical | 2003 |
Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Prospective Studies; R | 2003 |
Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
Topics: Acute Disease; Adult; Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Female; Hemor | 2003 |
Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Humans; Ris | 2003 |
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Dose-Response Relationship, Drug; Double-B | 2003 |
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzylamines | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2003 |
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE)
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Drug Thera | 2004 |
Sealing of the mediastinum with a local hemostyptic agent reduces chest tube duration after complete mediastinal lymph node dissection for stage I and II non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aprotinin; Carcinoma, Small Cell; Chest Tubes; Dalte | 2004 |
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.
Topics: Aged; Blood Coagulation Factors; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Human | 2004 |
Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Aged; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Schedule; Enoxa | 2004 |
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2005 |
Patient compliance with outpatient prophylaxis: an observational study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Ag | 2005 |
Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Angiography; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort | 2005 |
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty | 2005 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2006 |
The prophylaxis of medical patients for thromboembolism pilot study.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hospitalization; Humans; Inj | 2006 |
Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (AC
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Electric Countershock; Enoxaparin; Hepari | 2007 |
Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Humans; Mal | 2006 |
VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Spinal; Arthroplasty, Replacement, Knee; Aspirin; Combin | 2006 |
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin | 2006 |
Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Creatinine; Enoxap | 2007 |
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Blood Coagulation; Body Weight; Creatinine; Drug Administration Schedule; E | 2007 |
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Mi | 2007 |
Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Decision Sup | 2007 |
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Metho | 2007 |
Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Drug Administration Schedule; Echoc | 2007 |
Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Brain Ische | 2008 |
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl | 1994 |
Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hepa | 1994 |
Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.
Topics: Aged; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Prosthesis; H | 1993 |
Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran.
Topics: Adult; Dextrans; Digestive System Surgical Procedures; Double-Blind Method; Enoxaparin; Female; Huma | 1995 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans | 1996 |
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administration Schedule; E | 1996 |
The post-hospital discharge venous thrombosis risk of the orthopedic patient.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Hip Prosthesis; Humans; Patient Discharge; P | 1997 |
The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hip Prosthe | 1997 |
Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Enoxaparin; Female; Heparin; Human | 1997 |
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Double-Bl | 1997 |
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Elective Surg | 1998 |
Development of play-the-winner design: weighting and accumulation of information.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dextrans; Enoxaparin; Female; Humans; In | 1998 |
Thrombocytosis after prophylactic administration of enoxaparin: unexpected findings in a Polish prospective multicenter trial on the efficacy and safety of enoxaparin in the prevention of postoperative thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Humans; Middle Aged; Orthopedic Procedures; Platelet | 1999 |
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
The use of low molecular weight heparin in pediatric patients: a prospective cohort study.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Cohort Studies; Enoxaparin; Female; Humans; Inf | 2000 |
Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.
Topics: Anticoagulants; Blood Loss, Surgical; Canada; Colectomy; Double-Blind Method; Enoxaparin; Female; He | 2001 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Res | 2001 |
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2001 |
[The role of heparin in prevention of deep veins thrombosis and pulmonary artery thromboembolism in therapeutic regime patients].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Pulmonary Artery; Severity of Illne | 2001 |
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Topics: Adolescent; Anticoagulants; Antineoplastic Agents; Asparaginase; Blood Coagulation Factors; Child; C | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; F | 2001 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Heparin; Hepar | 2003 |
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, Low-Molecula | 1997 |
[Prospective randomized pilot study of ambulatory prevention of thromboembolism. 2 times 500 mg aspirin (ASS) vs. clivarin 1750 (NMH)].
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Aspirin; Casts, Surgical; Dose-Response Relationship, | 1998 |
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L | 2001 |
Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial.
Topics: Adult; Aged; Anticoagulants; Arthroscopy; Drug Administration Schedule; Female; Heparin, Low-Molecul | 2001 |
A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Heparin; Heparin, Low-Molecular-Weight; Hu | 2010 |
Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chemoprevention; Female; Hemorrhage; Heparin; | 2011 |
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, | 2011 |
Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement; Biomarkers; Blood Coagulation; Female; Fracture | 2003 |
Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Heparin; Heparin, Low-Molecular-Wei | 2006 |
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dalteparin; Double-Blind Method; Femal | 2021 |
[The BRIDGE study].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dalteparin; Double-Blind Method; Female; Humans; Injectio | 2016 |
Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dalteparin; Drug-Related Side Effects and A | 2009 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Topics: Aged; Aged, 80 and over; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2012 |
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetid | 2002 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Atrial Fl | 2003 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; Blood Loss, Surgical; Coh | 2004 |
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Coumarins; Dalteparin; Female; Heparin, L | 2005 |
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Ne | 2005 |
Changes in plasma coagulation markers with prophylactic treatment of low molecular weight heparin after cesarean section.
Topics: Adult; Biomarkers; Blood Coagulation; Cesarean Section; Dalteparin; Female; Fibrin Fibrinogen Degrad | 2005 |
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.
Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Catheters, Indwelling; Dalte | 2006 |
Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2006 |
Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Humans; Incidence; Male | 2006 |
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Double-Blind Method; Fema | 2007 |
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.
Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Combined Modality Therapy; Dalteparin; Disease-Free Su | 2008 |
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontan | 1994 |
A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Dalteparin; Drug Administration Schedule; Female; Fibrinolytic Agent | 1996 |
Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group.
Topics: Abdomen; Anticoagulants; Dalteparin; Elective Surgical Procedures; Hemorrhagic Disorders; Humans; Mu | 1996 |
Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery.
Topics: Anticoagulants; Dalteparin; Female; Genital Diseases, Female; Heparin; Humans; Injections, Subcutane | 1998 |
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
Topics: Adult; Dalteparin; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Pregnancy; Pr | 1998 |
Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Drug Monitoring; Female; Follow-Up | 2000 |
The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
Topics: Adult; Anticoagulants; Case-Control Studies; Dalteparin; Factor V; Female; Hemostasis; Hemostatics; | 2001 |
[Low molecular weight heparin (dalteparin) in treatment of patients with thromboembolism incidents].
Topics: Aged; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up | 2001 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement | 2002 |
Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Drug Labeling; Drug Monitoring; Factor Xa Inhibito | 2005 |
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Hepari | 1997 |
Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 1998 |
[Lengthened activated thromboplastin time in the course of tinzaparin therapy of accidental venous thromboembolism. Pilot study].
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 1998 |
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cross-Over Studies; Factor Xa Inhibitors; Femal | 2002 |
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; | 1996 |
Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heparin, Low-Molecular- | 1997 |
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cause | 2000 |
277 other studies available for dalteparin and Thromboembolism
| Article | Year |
|---|---|
Thromboembolic and bleeding complications in patients with oesophageal cancer.
Topics: Adenocarcinoma; Aged; Anticoagulants; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; E | 2020 |
[Prophylaxis of thrombohemorrhagic complications in surgical treatment of chemoresistant pulmonary tuberculosis].
Topics: Adult; Anticoagulants; Antitubercular Agents; Female; Hemorrhage; Humans; Hydroxyethylrutoside; Indo | 2014 |
50th ASH Annual Meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lenalidomide; Leukemia, Lymp | 2009 |
A step in the right direction, but one size might not fit all.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lung Neoplasms; Nadroparin; Pancreatic Neoplasms | 2009 |
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; | 2010 |
[Some aspects of abdominal surgical interventions in the presence of obesity].
Topics: Anticoagulants; Cholecystitis, Acute; Female; Follow-Up Studies; Hernia, Diaphragmatic; Hernia, Vent | 2008 |
Thrombophylaxis and bleeding complications after cesarean section.
Topics: Adult; Cesarean Section; Cohort Studies; Cross-Sectional Studies; Dalteparin; Drug Therapy, Combinat | 2012 |
The effect of various types low molecular weight heparins on fracture healing.
Topics: Animals; Dalteparin; Enoxaparin; Femoral Fractures; Femur; Fondaparinux; Fracture Healing; Heparin, | 2013 |
[Prophylactic and correctional measures for thromboembolic complications in performance of the upper extremity replantation and microvascular autotransplantation of combined complex of tissues].
Topics: Adolescent; Adult; Aged; Anticoagulants; Child; Female; Humans; Male; Microsurgery; Middle Aged; Nad | 2002 |
[Clinical effectiveness of nadroparin calcium in the surgical treatment of breast cancer].
Topics: Anticoagulants; Breast Neoplasms; Female; Humans; Mastectomy; Nadroparin; Retrospective Studies; Thr | 2003 |
[Two approaches to correction of disturbed hemostasis in patients with mechanical artificial heart valves at the long-term follow-up].
Topics: Aspirin; Blood Coagulation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Fol | 2004 |
[Hypovolemic shock during surgery caused by a rectus sheath hematoma].
Topics: Adenoma; Anticoagulants; Atrial Fibrillation; Hematoma; Humans; Intraoperative Complications; Male; | 2005 |
Enoxaparin vs. nadroparin for venous thromboembolism prevention: too close to tell?
Topics: Anticoagulants; Clinical Trials as Topic; Data Interpretation, Statistical; Enoxaparin; Fibrinolytic | 2006 |
'Syringe-in-the-pocket'--a new approach to the outpatient thromboembolic prophylaxis of recurrent atrial fibrillation.
Topics: Aged; Ambulatory Care; Atrial Fibrillation; Electric Countershock; Feasibility Studies; Female; Fibr | 2007 |
Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions.
Topics: Aged; Anticoagulants; Drug Eruptions; Fondaparinux; Humans; Hypersensitivity, Delayed; Injections, S | 2007 |
Letter 2: Prevention of perioperative thromboembolism in patients with atrial fibrillation (Br J Surg 2007; 94: 1351-1355).
Topics: Anticoagulants; Atrial Fibrillation; Heparin; Humans; Intraoperative Complications; Nadroparin; Risk | 2008 |
[Prevention of thrombosis with fraxiparin 0.3 after arthroscopic interventions].
Topics: Adolescent; Adult; Aged; Arthroscopy; Dose-Response Relationship, Drug; Drug Administration Schedule | 1995 |
[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Evaluation; Female; Heparin; Humans; Male; Middl | 1993 |
Low-molecular weight heparins.
Topics: Angina, Unstable; Animals; Anticoagulants; Antithrombins; Clinical Trials as Topic; Dalteparin; Enox | 1997 |
[Use of low molecular weight heparins].
Topics: Anesthesia, Epidural; Anesthesia, Obstetrical; Anticoagulants; Antithrombin III Deficiency; Cesarean | 1997 |
Effect of low-molecular-weight heparin on serum potassium.
Topics: Anticoagulants; Fibrinolytic Agents; Humans; Middle Aged; Nadroparin; Potassium; Thromboembolism | 1997 |
[Long-term prophylaxis of thromboembolism and fraxiparin].
Topics: Anticoagulants; Contraindications; Drug Administration Schedule; Heart Valve Prosthesis; Humans; Nad | 1997 |
[Thromboembolism prophylaxis in pregnancy and labor].
Topics: Anticoagulants; Drug Administration Schedule; Female; Heart Valve Prosthesis; Hemostasis; Humans; Na | 1996 |
[10 years of Fraxiparin. Milestones in the prophylaxis of thromboembolism].
Topics: Anticoagulants; Fibrinolytic Agents; Humans; Nadroparin; Thromboembolism | 1998 |
Aspirin and fraxiparine in the prevention of laser induced thrombosis in the presence of iodinated contrast media.
Topics: Animals; Aspirin; Contrast Media; Diatrizoate; Fibrinolytic Agents; Hemoglobins; Iodine Radioisotope | 1998 |
Low-molecular-weight heparin and thromboembolism in pregnancy.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; | 1999 |
[State of the art: low-molecular-weight heparin and beyond].
Topics: Anticoagulants; Biological Availability; Blood Coagulation Factors; Clinical Trials as Topic; Fibrin | 2000 |
Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cohort Studies; Disease-Free Survival; Female; Foll | 2001 |
[Thromboembolism prevention in acute myocardial infarction].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Care Units; Cross-Sectional St | 2001 |
Clinical experiences with low-molecular weight heparins in pediatric patients.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Enoxaparin; Factor Xa Inhibitors; Female; Hepar | 2001 |
[Prevention of thromboembolic complications in laparoscopic surgery].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Child; Female; Humans; Laparoscopy; Male | 2001 |
Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Confidence Intervals; Electric Countershock; Female; Hepa | 2011 |
Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin.
Topics: Adult; Anticoagulants; Arthroscopy; Female; Heparin, Low-Molecular-Weight; Humans; Knee Joint; Male; | 2007 |
Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Post | 2022 |
[Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter].
Topics: Adult; Aged; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling; Data Interpreta | 2009 |
Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Costs and Cost Analysis; Dec | 2004 |
Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug A | 2007 |
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Hemorrhage; H | 2022 |
Awareness and Perception of Thromboembolism and Thromboprophylaxis among Hospitalized Patients in Jordan.
Topics: Adult; Aged; Cross-Sectional Studies; Educational Status; Enoxaparin; Female; Fibrinolytic Agents; H | 2020 |
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
Topics: Aged; Aminopyridines; Antineoplastic Agents; Artifacts; Benzimidazoles; Breast Neoplasms; Coronary V | 2021 |
Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms.
Topics: Acute Kidney Injury; Algorithms; Anticoagulants; Child; Child, Preschool; Drug Monitoring; Enoxapari | 2021 |
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hemorrhage; Humans; Ma | 2021 |
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hospital Mortality; Hospitali | 2021 |
Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heart Ventricles; Heart-Assist D | 2021 |
CORR Insights
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Factor Xa Inhibitors; Humans; | 2017 |
Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Critical Care; Dose-Response Relationshi | 2018 |
Enoxaparin Dosing and the Prevention of Venous Thromboembolism in Plastic Surgery Patients.
Topics: Anticoagulants; Enoxaparin; Humans; Plastic Surgery Procedures; Surgery, Plastic; Thromboembolism; V | 2017 |
Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Enoxaparin; Factor Xa; Female; Hospitalization; | 2018 |
Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis.
Topics: Abortion, Spontaneous; Adult; Anemia, Sickle Cell; Anticoagulants; Birth Weight; Cross-Sectional Stu | 2018 |
Women's views, adherence and experience with postnatal thromboprophylaxis.
Topics: Adult; Anticoagulants; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Humans; Intermitte | 2019 |
Primary thromboprophylaxis in hospitalized children: A multi-center retrospective analysis.
Topics: Adolescent; Anticoagulants; Child; Enoxaparin; Female; Hemorrhage; Humans; Male; Mechanical Thrombol | 2019 |
[Parkes-Weber syndrome and pregnancy: anaesthetic implications].
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; Arteriovenous Malformations; Emb | 2013 |
Can enoxaparin reduce thromboembolism related events after primary TKA in Asian patients?
Topics: Aged; Arthritis; Arthroplasty, Replacement, Knee; Asian People; Enoxaparin; Female; Fibrinolytic Age | 2013 |
Additional considerations to precede selection of enoxaparin therapy.
Topics: Enoxaparin; Female; Humans; Male; Renal Insufficiency; Thromboembolism | 2013 |
Additional considerations to precede selection of enoxaparin therapy--reply.
Topics: Enoxaparin; Female; Humans; Male; Renal Insufficiency; Thromboembolism | 2013 |
Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats.
Topics: Animals; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Fondaparinux; Fracture Healing; Male; M | 2013 |
[Thromboprophylaxis in medical patients: Which modifications with the new oral anticoagulants?].
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivarox | 2013 |
Effects of enoxaparin and unfractionated heparin in prophylactic and therapeutic doses on the fertility of female Wistar rats.
Topics: Animals; Anticoagulants; Enoxaparin; Female; Fertility; Fetus; Hemorrhage; Heparin; Male; Placenta; | 2014 |
Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2015 |
Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Hepa | 2014 |
[Perioperative control of vitamin K antagonists in elective surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Elective Surgical Procedures; Enoxapar | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
Heparin resistance and coagulation activation rebound effect after anticoagulant withdrawal: beneficiary effect of adjuvant antiplatelet therapy.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation; Case-Control Studies; Clopi | 2016 |
Bridging with half-therapeutic dose enoxaparin in outpatients with left ventricular assist devices and sub-therapeutic international normalized ratios.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Feasib | 2015 |
[Prevention with lower bleeding risk].
Topics: Adult; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Thromboembolism | 2015 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre | 2015 |
The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism.
Topics: Arterial Occlusive Diseases; Brachial Artery; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2015 |
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2016 |
[Enoxaparin dosage in extreme obesity by monitoring anti-Xa factor].
Topics: Anticoagulants; Enoxaparin; Factor Xa; Humans; Male; Middle Aged; Monitoring, Physiologic; Obesity, | 2016 |
Repeated Thrombosis After Synthetic Cannabinoid Use.
Topics: Adult; Anticoagulants; Aspirin; Cannabinoids; Enoxaparin; Female; Humans; Infarction; Platelet Aggre | 2016 |
The effects of enoxaparin on the liver in experimental pneumoperitoneum model.
Topics: Animals; Anticoagulants; Carbon Dioxide; Disease Models, Animal; Enoxaparin; Female; Liver; Oxidativ | 2016 |
Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure.
Topics: Anticoagulants; Arterial Occlusive Diseases; Blood Coagulation; Blood Coagulation Tests; Computed To | 2017 |
IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
Topics: Anticoagulants; Child; Child, Preschool; Clinical Protocols; Critical Illness; Drug Administration S | 2017 |
Editorial: Antithrombotic management early after mechanical heart valve replacement.
Topics: Anticoagulants; Cardiovascular Surgical Procedures; Dose-Response Relationship, Drug; Enoxaparin; Fi | 2008 |
A practical approach for bridging anticoagulation after mechanical heart valve replacement.
Topics: Aged; Anticoagulants; Aortic Valve; Cardiovascular Surgical Procedures; Dose-Response Relationship, | 2008 |
Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Middle Aged; Obesity, Morbid; Plastic Surgery Pro | 2008 |
Letter 2: use of enoxaparin results in more haemorrhagic complications after breast surgery than unfractionated heparin (Br J Surg 2008; 95: 834-836).
Topics: Anticoagulants; Breast Diseases; Enoxaparin; Female; Hematoma; Humans; Postoperative Hemorrhage; Thr | 2008 |
Letter 3: use of enoxaparin results in more haemorrhagic complications after breast surgery than unfractionated heparin (Br J Surg 2008; 95: 834-836).
Topics: Anticoagulants; Breast Neoplasms; Enoxaparin; Female; Hematoma; Humans; Postoperative Hemorrhage; Th | 2008 |
The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin.
Topics: Aged; Anticoagulants; Cerebral Angiography; Cohort Studies; Enoxaparin; Female; Heparin; Humans; Mal | 2009 |
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Topics: Administration, Oral; Blood Coagulation; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Huma | 2008 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap | 2008 |
[Unusual reason for unilateral (corrected) Raynaud's phenomenon with intensification when the arms are elevated].
Topics: Adult; Aneurysm; Anticoagulants; Aspirin; Cervical Rib Syndrome; Diagnosis, Differential; Enoxaparin | 2009 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Dosage Calculations; | 2009 |
Air travel and pulmonary embolism: "economy class syndrome".
Topics: Adult; Aircraft; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Fac | 2009 |
Dabigatran: new drug. Continue to use heparin, a better-known option.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab | 2009 |
High incidence of complications from enoxaparin treatment after arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2010 |
Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin.
Topics: Anticoagulants; Delivery, Obstetric; Drug Administration Schedule; Drug Monitoring; Enoxaparin; Fema | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Knee; Drug Monitoring; Enoxaparin; Factor Xa I | 2009 |
Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Topics: Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Female; Hear | 2009 |
Living donor liver transplantation: usefulness of hemostatic and prothrombotic screening in potential donors.
Topics: Adult; Anticoagulants; Child, Preschool; Enoxaparin; Female; Fibrinogen; Hemostatics; Humans; Infant | 2009 |
Obstetric patient on Lovenox therapy: evidence of heparin activity at 24 hours.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Thro | 2010 |
Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Confidence I | 2010 |
Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
Topics: Adolescent; Anticoagulants; Asparaginase; Catheterization, Central Venous; Child; Child, Preschool; | 2010 |
Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
Topics: Adolescent; Age Distribution; Age Factors; Anticoagulants; Child; Child, Preschool; Drug Administrat | 2010 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 2010 |
[Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2010 |
Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Loss, Surgic | 2010 |
[Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Atrial Fibrillation; Drug T | 2010 |
How should we define major bleeding events in thromboprophylaxis?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Bandages; Enoxaparin; Hemorrhage; Heparin, Low-Molec | 2010 |
Metastatic osteosarcoma presenting as a single pulmonary microembolus.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2011 |
Non-therapeutic anti-FXa levels are common among medical ward patients treated with enoxaparin.
Topics: Aged; Anticoagulants; Autoantibodies; Enoxaparin; Factor Xa; Female; Fibrinolytic Agents; Humans; Is | 2011 |
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail | 2011 |
Tapentadol for pain; enoxaparin after prosthetic valve replacement.
Topics: Anticoagulants; Enoxaparin; Heart Valve Prosthesis Implantation; Humans; Pain; Phenols; Tapentadol; | 2011 |
[ADOPT study. Longer thrombosis prevention in internal medicine patients has no advantage].
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Injections, Subcutane | 2011 |
Reference ranges for thromboelastography (TEG(®) ) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia*.
Topics: Adolescent; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anticoagulants; Blood Coagulation; B | 2012 |
What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?
Topics: Aged; Anticoagulants; Chemotherapy, Adjuvant; Chi-Square Distribution; Combined Modality Therapy; Dr | 2012 |
Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas.
Topics: Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Follow-Up Studies; Heart Valve Prosthesis Implant | 2013 |
Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Case-Control | 2012 |
Postsplenectomy thromboembolic disease in congenital sideroblastic anaemia.
Topics: Anemia, Sideroblastic; Anticoagulants; Diagnosis, Differential; Enoxaparin; Humans; Male; Splenectom | 2010 |
Enoxaparin outcomes in patients with moderate renal impairment.
Topics: Aged; Anticoagulants; Creatinine; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up St | 2012 |
Moderate renal impairment and risk of bleeding with anticoagulation.
Topics: Enoxaparin; Female; Humans; Male; Renal Insufficiency; Thromboembolism | 2012 |
Foam sclerotherapy with enoxaparin prophylaxis in high-risk patients with postthrombotic syndrome.
Topics: Anticoagulants; Combined Modality Therapy; Drug Administration Schedule; Enoxaparin; Humans; Polidoc | 2013 |
Fondaparinux versus enoxaparin for prevention of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux: new preparation. No better than LMWH in preventing pulmonary embolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Evaluation; En | 2003 |
A safety analysis of thromboprophylaxis in acute medical illness.
Topics: Acute Disease; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Risk Factors; Safety; Thromb | 2003 |
[Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report].
Topics: Aged; Anticoagulants; Bursitis; Drug Administration Schedule; Elbow Joint; Enoxaparin; Epigastric Ar | 2003 |
Anticoagulation of pregnant women with mechanical heart valves.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Valve Prosthesis; Hep | 2003 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin | 2003 |
Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.
Topics: Acenocoumarol; Anticoagulants; Blood Loss, Surgical; Cohort Studies; Contraindications; Enoxaparin; | 2003 |
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients.
Topics: Adult; Aged; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Obesity; Pe | 2003 |
More nonsense.
Topics: Anticoagulants; Dental Care for Chronically Ill; Enoxaparin; Fatal Outcome; Female; Humans; Male; Ne | 2003 |
Venous thromboembolic risk and prevention in acute medical illness.
Topics: Acute Disease; Aged; Anticoagulants; Cardiac Output, Low; Enoxaparin; Female; Hospitalization; Human | 2003 |
[Evaluation of selected parameters of blood coagulation and fibrinolysis system in patients undergoing total hip replacement surgery with normovolemic hemodilution procedure and standard enoxaparine prophylaxis].
Topics: Aged; alpha-2-Antiplasmin; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Blood Coag | 2003 |
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Topics: Anticoagulants; Antithrombin III; Catheters, Indwelling; Cohort Studies; Coronary Disease; Dose-Resp | 2003 |
The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Cos | 2003 |
Best evidence in anesthetic practice: prevention: fondaparinux is better than enoxaparin for prevention of major venous thromboembolism after orthopedic surgery.
Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Fondaparinux; Humans; Orthopedic Procedures; Po | 2003 |
Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2003 |
Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Topics: Administration, Oral; Echocardiography, Transesophageal; Electric Countershock; Enoxaparin; Heparin; | 2003 |
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.
Topics: Acute Disease; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heart Failure; Hospitalization | 2004 |
An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
Topics: Anticoagulants; Costs and Cost Analysis; Decision Trees; Drug Costs; Enoxaparin; Heparin; Heparin, L | 2004 |
Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Dose-Response Relationsh | 2004 |
Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hemorrhage; Humans; Infant, Low Birth | 2004 |
Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Costs and Cost Analysis; Elective Surgical Procedure | 2004 |
Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Case-Contr | 2004 |
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin | 2004 |
Risk factors for venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Hospitalization; Humans; Patient Selection; Risk Factors; Thromboembolis | 2004 |
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Enoxap | 2004 |
Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit | 2005 |
Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heart Valve | 2005 |
[Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study].
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Inc | 2005 |
Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Anticoagulants; Enoxaparin; Humans; International Normalized Ratio; Orthopedic Procedures; Postopera | 2005 |
Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers.
Topics: Anticoagulants; Burn Units; Burns; Dalteparin; Enoxaparin; Health Surveys; Heparin; Humans; Risk Fac | 2005 |
Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Topics: Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Hum | 2005 |
Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Topics: Adult; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2005 |
Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states.
Topics: Aged; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Fo | 2005 |
Once atrial fibrillation, always oral anticoagulation?
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; | 2007 |
Inherited thrombophilia: treatment during pregnancy.
Topics: Adult; Anticoagulants; Birth Weight; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Feta | 2006 |
[Thromboembolisms endanger the internist patients, too: who needs heparin].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Family Practice; Female; Fibrinolytic Age | 2006 |
[Prophylaxis of venous thromboembolism in acutely ill medical patients].
Topics: Acute Disease; Aged; Dalteparin; Enoxaparin; Fibrinolytic Agents; Health Status; Humans; Middle Aged | 2006 |
Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Topics: Anticoagulants; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Germany; Hemorrhage; Hospitals; Human | 2006 |
[Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients].
Topics: Administration, Oral; Age Factors; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2006 |
[Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer].
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Enoxapari | 2006 |
Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Creatinine; Critical Care; | 2006 |
A fatal case of enoxaparin induced skin necrosis and thrombophilia.
Topics: Aged; Anticoagulants; Diagnosis, Differential; Drug Eruptions; Enoxaparin; Factor V; Factor VIII; Fa | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari | 2006 |
Massive subchorionic hematoma associated with enoxaparin.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Cesarean Section; Chorion; Enoxaparin; Factor Xa Inhibit | 2006 |
Continuous peripheral nerve block in combat casualties receiving low-molecular weight heparin.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Iraq; Male; Middle | 2006 |
Reversal of anti-thrombin activity using protamine sulfate. Experience in a neonate with a 10-fold overdose of enoxaparin.
Topics: Drug Overdose; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infant, Newborn; Protamines; Thrombo | 2007 |
Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients.
Topics: Anticoagulants; Blood Coagulation; Case-Control Studies; Dose-Response Relationship, Drug; Drug Resi | 2007 |
Selecting an agent for prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Enoxaparin; Fibrinolytic Agents; Formularies, Hos | 2006 |
Summaries for patients. Safety of surgery during bridging anticoagulation therapy with low-molecular-weight heparin.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Hemorrhage; Human | 2007 |
Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Hemorrhage; Human | 2007 |
Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis.
Topics: Adolescent; Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2007 |
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Phleb | 2007 |
Enoxaparin as bridging anticoagulant treatment in cardiac surgery.
Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Intraoperative Care; M | 2008 |
Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factor Inhibitors; Body Weight; Drug Moni | 2007 |
Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry.
Topics: Aged; Anticoagulants; Aortic Valve; Enoxaparin; Feasibility Studies; Heart Valve Prosthesis; Heart V | 2007 |
Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study.
Topics: Adolescent; Anticoagulants; Area Under Curve; Child; Child, Preschool; Enoxaparin; Humans; Infant; T | 2007 |
[Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Sched | 2007 |
Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin.
Topics: Adult; Enoxaparin; Fibrinolytic Agents; Gastric Bypass; Heparin; Humans; Laparoscopy; Middle Aged; P | 2007 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
[Stroke. Enoxaparin sodium inhibits venous thromboembolism compared to unfractionated heparin].
Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Randomized Controlled Trials as Topic; Stroke; Thromboe | 2007 |
Use of enoxaparin results in more haemorrhagic complications after breast surgery than unfractionated heparin.
Topics: Anticoagulants; Breast Diseases; Enoxaparin; Female; Hematoma; Humans; Postoperative Hemorrhage; Thr | 2008 |
[Enoxaparin (clexane) in the prevention of thromboembolism after total hip replacement].
Topics: Adult; Aged; Enoxaparin; Female; Hip Prosthesis; Humans; Injections, Subcutaneous; Male; Middle Aged | 1993 |
Comment: enoxaparin--the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.
Topics: Enoxaparin; Humans; Postoperative Complications; Thromboembolism; Thrombophlebitis; Warfarin | 1994 |
Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Hip Prosthesis; Humans; Knee Pr | 1994 |
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin; Hip Prosthesis; Humans; Postoperative Complications; | 1994 |
Low-molecular-weight heparins: do good things really come in small packages?
Topics: Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Thromboembo | 1993 |
Low molecular weight heparin for obstetric thromboprophylaxis.
Topics: Drug Costs; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Complica | 1994 |
The use of low molecular weight heparin for thromboprophylaxis in pregnancy.
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Female; Gestational Age; Heparin; Humans; Pregn | 1994 |
Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Enoxaparin; Female; Fetal Death; Heparin; Huma | 1995 |
Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies.
Topics: Adult; Antiphospholipid Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Humans; Labor, Obstetric; | 1996 |
Home treatment of deep venous thrombosis.
Topics: Anticoagulants; Enoxaparin; Home Nursing; Humans; Injections, Intravenous; Randomized Controlled Tri | 1996 |
Enoxaparin as prophylaxis against thromboembolism after total hip replacement.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Radiography; Thromboembolism; Thrombophlebitis | 1997 |
Enoxaparin as prophylaxis against thromboembolism after total hip replacement.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Injections, Subcutaneous; Thromboembolism; Warfa | 1997 |
Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low-molecular-weight heparin: enoxaparin.
Topics: Anticoagulants; Bone and Bones; Enoxaparin; Hemorrhage; Hip Prosthesis; Humans; Joint Prosthesis; Kn | 1997 |
Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
Topics: Anticoagulants; Bone Density; Cohort Studies; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Pregn | 1997 |
Low-molecular-weight heparin in the management of Trousseau's syndrome.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Synd | 1997 |
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 1998 |
Enoxaparin in neurosurgical patients.
Topics: Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Hemorrhage; Heparin; Humans; Thromb | 1998 |
Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Topics: Anticoagulants; Enoxaparin; Heparin; Hip Prosthesis; Humans; Thromboembolism; Warfarin | 1996 |
Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Topics: Anticoagulants; Canada; Colorectal Surgery; Cost-Benefit Analysis; Digestive System Surgical Procedu | 1999 |
Use of enoxaparin for the chronically anticoagulated patient before and after procedures.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Hum | 1999 |
Low molecular weight heparin for thromboprophylaxis during caesarean section.
Topics: Adult; Antibodies; Blood Coagulation; Cesarean Section; Delivery, Obstetric; Enoxaparin; Factor Xa; | 1999 |
Enoxaparin for the prevention of VT in acutely ill patients.
Topics: Acute Disease; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Hospitalization; Humans; Pulm | 1999 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Humans; Risk; Thromboembolism | 2000 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Placebos; Thromboembolism | 2000 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Thromboemb | 2000 |
Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Costs and Cost Analysis; D | 2000 |
Care for life. Central is the patient.
Topics: Angina, Unstable; Anticoagulants; Awards and Prizes; Death, Sudden, Cardiac; Enoxaparin; Germany; Hu | 2000 |
[Anti-Xa activity during administration of low-molecular weight heparin in the prevention of postoperative thromboembolic complications].
Topics: Adult; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 1999 |
[Prevention of embolism in severely ill internal medicine patients. In heart failure it is better to use low molecular weight heparin].
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Germany; Heart Failure; Humans; Thromboembolis | 1999 |
[Thrombosis prophylaxis in orthopedic surgery].
Topics: Dalteparin; Dextrans; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Heparin, Low-Molecular-Wei | 2000 |
Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure.
Topics: Adult; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Cardiac Catheterization; Cardiopulmo | 2000 |
[1999 Robert Koch Drug Award for enoxaparin. Safely preventing thromboembolism].
Topics: Anticoagulants; Awards and Prizes; Enoxaparin; Germany; Humans; Thromboembolism | 1999 |
[Internet research simplified. Thrombosis and embolism--rapid information].
Topics: Anticoagulants; Enoxaparin; Humans; Internet; Thromboembolism | 2000 |
Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Gestational Age; Humans; Pregnancy | 2000 |
Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism.
Topics: Animals; Antibodies; Anticoagulants; Balloon Occlusion; Dalteparin; Diagnostic Imaging; Disease Mode | 2000 |
Duration of thrombosis prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Hip Fractu | 2001 |
Enoxaparin and prevention of venous thrombo-embolism in medical units: new indication. No tangible benefit.
Topics: Anticoagulants; Clinical Trials as Topic; Drug Approval; Enoxaparin; Fibrinolytic Agents; France; Hu | 2000 |
[Application of clexane for prophylaxis of thromboembolic complications in surgery of morbid obesity].
Topics: Adult; Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Female; Humans; Male; Middl | 2001 |
[What kind of heparin treatment in venous thromboembolic disease?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Fibrinolytic Agents; Humans; Middle Aged; Th | 2001 |
Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Topics: Adult; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Infant, Newborn; Intracrania | 2001 |
A new therapeutic strategy for electrical cardioversion of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clinical Protocols; Echocardiography, Transesophageal; El | 2001 |
Choosing a parenteral anticoagulant agent.
Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecu | 2001 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hip Fractures; Humans; | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharide | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharide | 2002 |
Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Humans; Thromboembolism; Venous Thrombosis | 2002 |
Risks and benefits of chemoprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Risk Assessment; Thromboembolis | 2002 |
Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Humans; Intracranial Hemorrh | 2002 |
Preclinical studies on a low molecular weight heparin.
Topics: Animals; Anticoagulants; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug | 1996 |
Low-molecular-weight heparin in patients with deep-vein thrombosis.
Topics: Anticoagulants; Heparin; Heparin, Low-Molecular-Weight; Humans; Partial Thromboplastin Time; Seconda | 2001 |
Low-molecular-weight heparin in patients with deep-vein thrombosis.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Thrombosis | 2001 |
[Possible effect low molecular weight heparin on survival time. New chances for cancer patients?].
Topics: Anticoagulants; Clinical Trials as Topic; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Injecti | 2003 |
Early antithrombotic prophylaxis with low molecular weight heparin in neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Brain Injuries; Brain Neoplasms; Cerebrospinal Fluid Shunts; Contrai | 2003 |
[Marcumarized patient must have surgery. Playing it safe with low molecular weight heparin bridging].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Heparin, Low-Molecul | 2005 |
[Internist patients are strongly thrombosis endangered. CERTIFY study has arrived].
Topics: Age Factors; Aged; Anticoagulants; Antifibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; | 2007 |
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; C | 2020 |
Heartache and bellyache: limited English proficiency perpetuating recurrent thromboembolic events.
Topics: Anticoagulants; Communication Barriers; Dalteparin; Female; Humans; Language; Medication Adherence; | 2015 |
Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.
Topics: Administration, Oral; Animals; Aspirin; Bioprosthesis; Clopidogrel; Dalteparin; Disease Models, Anim | 2008 |
Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Critical Illne | 2009 |
Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Defibrillators, Implantable; Female; Fibrinolyt | 2009 |
Dalteparin in total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dalteparin; Humans; Postopera | 2010 |
[Treating severe acute anemia due to vaginal bleeding in the Jehovah's Witness: a report of 2 cases].
Topics: Adult; Anemia; Anti-Anxiety Agents; Anticoagulants; Cervix Uteri; Combined Modality Therapy; Contrac | 2009 |
Anticoagulant response after dalteparin overdose.
Topics: Adult; Anticoagulants; Calibration; Creatinine; Dalteparin; Drug Overdose; Female; Heparin; Humans; | 2010 |
Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Dalteparin; Female; Hea | 2011 |
Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Kn | 2011 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Thromboprophylaxis with low molecular weight heparin in thrombophilia-complicated pregnancy.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Female; Humans; Pregnancy; Pregnancy C | 2002 |
Dalteparin after total knee replacement.
Topics: Arthroplasty, Replacement, Knee; Dalteparin; Humans; Postoperative Care; Retrospective Studies; Thro | 2002 |
Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
Topics: Acute Disease; Adult; Anticoagulants; Dalteparin; Factor Xa; Female; Humans; Norway; Pregnancy; Preg | 2003 |
Interpretation of findings about dalteparin interchange.
Topics: Arthroplasty, Replacement, Knee; Dalteparin; Humans; Postoperative Care; Thromboembolism | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Bias; Dalteparin; Humans; International Normali | 2003 |
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor | 2004 |
Anticoagulation interruptus: not without risk.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri | 2004 |
[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].
Topics: Adult; Age Factors; Aged; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Female; Fibrinolytic | 2004 |
Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro.
Topics: Alkaline Phosphatase; Anticoagulants; Cells, Cultured; Dalteparin; Fluoresceins; Fondaparinux; Gene | 2005 |
[Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)].
Topics: Adult; Anticoagulants; Complement Factor H; Dalteparin; Fondaparinux; Humans; Middle Aged; Polysacch | 2004 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Dalteparin; Female; Humans; Internation | 2005 |
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Humans; Logistic Models; Male; Multivar | 2005 |
Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
Topics: Abdomen; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Humans; | 2005 |
Safety of outpatient dalteparin therapy in veterans with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Heart Valve Prosthesis; Hemorrhage; Humans; Mal | 2005 |
Catheter-related clotting not reduced by dalteparin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Clinical Trials, Phase III as | 2006 |
Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
Topics: Adult; Anticoagulants; Canada; Dalteparin; Female; Humans; Male; Middle Aged; Neoplasms; Quality of | 2006 |
Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Protocols; Dalteparin; Feasibil | 2007 |
Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Heart Valve Prosthesis Implantation; | 2007 |
[Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
Topics: Adult; Anticoagulants; Cesarean Section; Chondroitin Sulfates; Cross Reactions; Dalteparin; Dermatan | 1995 |
Diagnosis of APC resistance in patients on standard or low molecular weight heparin.
Topics: Anticoagulants; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Disease Susceptibility; Factor V | 1996 |
Dalteparin in emergency patients to prevent admission prior to investigation for venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Cost Savings; Daltepari | 1999 |
[Hematoma of the right rectus abdominis in relation to treatment with low-molecular-weight heparin].
Topics: Aged; Anticoagulants; Dalteparin; Female; Hematoma; Humans; Injections, Subcutaneous; Muscular Disea | 2000 |
Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Gestational Age; Heparin; Humans; P | 2001 |
[The role of low molecular weight heparin (fragmin) in the prophylaxis and treatment of venous thromboembolism in major abdominal operations].
Topics: Dalteparin; Digestive System Surgical Procedures; Heparin, Low-Molecular-Weight; Humans; Pulmonary E | 2000 |
[Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy].
Topics: Adolescent; Adult; Antithrombin III; Dalteparin; Dose-Response Relationship, Drug; Female; Fibrin Fi | 2002 |
Unresolved issues in the prevention and treatment of venous thromboembolism.
Topics: Clinical Trials as Topic; Dalteparin; Double-Blind Method; Drug Administration Schedule; Factor VIIa | 2002 |
Inflammatory bowel disease and thromboembolism. Is inflammation at the centre of the clot?
Topics: Adult; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Inflammation; Inflammatory Bow | 2013 |
[Long-term treatment of venous thromboembolism and prevention of relapse in cancer patients].
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasm Recurrence, Loc | 2015 |
Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Fem | 2011 |
Venous thromboembolism. Prophylaxis on a Saturday morning in a district hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bandages; Female; Fibrinolytic Agents; Guideline Adheren | 2002 |
Tinzaparin in the treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Fibri | 2003 |
Readmission after hysterectomy and prophylactic low molecular weight heparin: retrospective case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Female; Heparin, Low-Molecular | 2006 |
The outcome of ambulatory DVT management using a multidisciplinary approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Disease Management; Drug Evaluation; Fe | 2001 |
Prolonged prophylaxis after joint replacement: another step sideways?
Topics: Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administratio | 2000 |